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ABSTRACT 
  
You've got to think about big things while you're doing small things, so that all the small 
things go in the right direction. — Alan Toffler, Future Shock 
 
In recent decades we have seen a major disruption to all major industries as a result of 
changing consumer demands, consumer empowerment, big data, and shifting demographics. 
Evidence of this can be seen in the disruption of major industries such as the automotive 
industry, retail, banking and manufacturing. Data is enabling a shift in power from large 
companies to smaller, emerging players.  
 
Big Pharma has long enjoyed a privileged position, having grown with the healthcare system 
since its inception in the United States. We are at a moment in time where there is emerging 
capability to bring about radical change in the way that healthcare is delivered as a result of new 
technologies and the advancement of science. Digital Therapeutics and alternatives to 
pharmacological response to disease are becoming not only viable, but necessary, to contain 
costs and improve health outcomes. These changes are creating a risk of disruption for Big 
Pharma, if there is not a radical reassessment of organizational strategies and investment.  
  
Using the Three Horizon’s Foresight Methodology, this paper explores the needs, barriers and 
opportunities for each major stakeholder – pharma, emerging technology players, payers, 
patients and providers – given an overview to the present situation, the ideal future and 
presenting strategies to bridge these two horizons. The result is an understanding of the potential 
areas of disruption to health therapeutics industry and an understanding of how the 
pharmaceutical industry may adapt to build resiliency by transitioning and rethinking its core 
product, facilitating and partnering with emerging players, and moving towards a strategy of 
improving health outcomes (real value creation) rather than revenue increases and identifying 
new revenue opportunities in the process.  
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ANALYTICAL TOOLS 
Why a foresight study?  
 
In order to uncover areas of potential disruption as a result of empowered emerging players in 
healthcare, it was necessary to look at not only the present situation but also some of the 
emerging changes, challenges, and opportunities on the horizon. This is critical for any large, 
entrenched, and complex system, not only because of breadth of opportunities for disruption and 
change, but also because of the time horizons upon which investments and planning are 
facilitated. The healthcare system, being extremely complex and entrenched, requires new 
patterns of thinking and frameworks to assist in navigating the uncertainty of the future.  
 
“Shifting to a new pattern involves some form of strategic thinking and foresight.” (Miller, 
2007). Foresight can be classified into four types, according to the extent to which the decision 
maker has agency to do things and the degree of uncertainty they are facing. According to 
Anthony Hodgson, co-creator of the Three Horizon’s method, the four types include Forecast 
Plans, Scenarios, Reflexive Futures, and Roadmaps. Hodgson and Sharpe developed the Three 
Horizon’s model to fit into the Reflexive Futures category which fits into the High Uncertainty 
and High Agency in the quadrant below.  (Hodgson & Midgley, 2015) 
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Figure 1 - Four Broad Categories of Foresight Method (Hodgson & Midgley, 2015) 
 
Three Horizons Model  
“Giants are not what we think they are. The same qualities that appear to give them strength are 
often the sources of great weakness.” Malcolm Gladwell 
 
In order to analyze the future of the pharmaceutical industry, the foresight framework “Three 
Horizons Model” was adopted. The Three Horizons model is useful in analyzing complex 
systems, especially those that involve many, large stakeholders that operate with different 
incentive systems, such as the healthcare system. 
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Operational research methods that are linear and algorithmic are useful in the more deterministic 
and predictive world of forecasts and extrapolation. Systems methods that account for dynamic 
feedback correlate better with the world of roadmaps, where performance on the pathway is 
subject to strong feedback influences. In the domain of scenarios, where there is high 
uncertainty, there is also increased dependency on human judgement, so approaches like critical 
systems heuristics and soft systems methodology fit well (Hodgson & Midgley, 2015). 
 
The Three Horizons model was developed by UK Foresight Intelligent Infrastructure Systems 
(IIS) Project (Shultz, 2013). This tool helps us think about the future by helping us “group 
systemic patterns to identify which of the dominant patterns are no longer fit for purpose, how 
the emerging trends can shape the future, and what visionary action is needed to collectively 
move us towards a viable future.” In a facilitated group environment, the model would allow us 
to gather perspectives from a large group of stakeholders, synthesize common understandings in 
order to prioritize action, and give the group a common language.  
 
 
Figure 2 The Three Horizons (Hodgson & Midgley, 2015) 
4 
 
 
As a foresight methodology, the tool is used as an analytical framework to make speculative 
claims about the potential future and to guide future areas of study.  
An alternative approach is to organise systems methods from the perspective of the three 
horizons. The qualitative distinctions between the horizons also suggests that different systems 
methods may be more suited to problem-solving and decision-making according to the horizon 
perspective adopted by the decision maker. A broad representation of this is given in Figure 4. 
This is not intended to be comprehensive or finalized, but rather to suggest an approach for 
further investigation (Hodgson & Midgley, 2015). 
 
In the case of this study, the Three Horizons Model was used to structure research findings from 
the literature review. In place of a broad stakeholder discussion, the researcher used a literature 
review to get a sense of some of the major challenges facing the pharmaceutical industry today 
and some of the emerging opportunities for digital therapeutics as an alternative. This tool was 
chosen because it can accommodate a high-level system analysis while also offering the 
opportunity to dive deep into certain opportunities for intervention.  
 
The Three Horizons Model looks at three large categories as can be seen in the table below: 
What is broken now? Where are we currently seeing evidence of the future? What is worthwhile 
keeping and how might we bridge that gap? Each section references critical nodes of the broader 
system that will be affected or may have to be disrupted in order to usher in the next generation 
of care. This exploration was done to provide a framework for understanding some of the 
challenges, barriers, and opportunities that exist across the healthcare ecosystem.   
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Figure 3 Description of Three Horizons (Hodgson & Midgley, 2015) 
 
In order to answer these questions, a variety of other research methods are employed, including a 
literature review, horizon scanning, and trend analysis. The findings are organized along the lines 
of the questions laid out in the table above in order to generate new insight, reframe existing 
problems, and identify opportunities for further investigation or research. The image below 
illustrates how a Three Horizons method may look during the research visualization process.  
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Figure 4 Three Horizons in Practise (Hodgson & Midgley, 2015) 
  
Literature Review & Environmental Scan — A literature review and environmental scan was 
conducted over the course of two years, spanning journals, newspapers, magazines, newsletters, 
and technology reviews. The review resulted in a wide array of information that gave insight into 
some of the broader challenges, as well as hope and opportunities for the future of the healthcare 
system. Quotes and personal points from authors and experts were leveraged in place of points of 
view that would have been gathered from an interview. The literature review was largely used to 
inform the First Horizon, “What is broken now?” and “Where do we see evidence of the future?”  
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Horizon Scan & Trend Analysis — A horizon scan and trend analysis was done in conjunction 
with the literature review. A scan is a tool used to identify emerging changes. According to 
Wendy Shultz, a high-quality scan has the following three qualities: it identifies an emerging 
issue that is objectively new even to experts; confirms or is confirmed by additional scan hits; 
and has been identified in time for social dialogue, impact assessment, and policy formation. 
(Shultz, 2013) These scan signals helped to inform the Third Horizon, and to give a sense of 
some of the ways in which individualized medicine and digital therapeutics are likely to evolve. 
The scan was organized into the VERGE framework as a means to understand the potential 
impacts and implications; eventually the key points were used to bring context to the potential 
future and an understanding of what the ideal future might be 
(Visionforesightstrategy.wordpress.com, 2018).  
  
Systems Diagrams & Archetypes — Systems thinking thought leader and researcher, William 
Braun, introduces the systems archetypes in his paper Systems Archetypes. Their purpose is to 
give “insight into patterns of behaviour, themselves reflective of the underlying structure of the 
system being studied.” (Braun, 2002) The archetypes can be used both to diagnose and to give 
perspective on a problem. They help us recognize patterns of behaviour that are already present 
in the organizations and can give some insight into underlying systems or processes which may 
be invisible, informal, or deeply embedded in a systems structure. In order to breakdown the 
complexity of certain aspects of the healthcare system and especially the relationships between 
different actors within the system, the researcher uses systems archetypes and process diagrams 
to help characterize some of the behavioural patterns within the system. 
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Three Horizon Contents Summary:  
FIRST HORIZON 
What is broken now?  
This section explores the development of the pharmaceutical industry and aspects of the 
ecosystem in which it operates that are creating barriers to innovation, encouraging incremental 
rather than the necessary transformational approach to innovation.  
 
1. Discovery - Pharma and risk adapted corporate players/funders 
The process and cost of discovering and innovating new treatments and cures is disincentivizing 
pharma to take a radical approach to therapeutic innovation and instead focus on prolonging 
profitability of current assets, investing in marketing and “blockbuster” medications rather than 
pursue innovative or truly individualized therapies.  
•   The Drugs Don’t Work: Imprecision Medicine – a description of the development of the 
evolution of pharmaceutical industry and the drug discovery process. This section 
explores how the growth of pharma alongside regulatory bodies and the broader 
healthcare system evolved into the current system.  
•   Generics Industry – an exploration of the ways in which the generics industry may inhibit 
pharmaceutical product innovation.  
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2. Payers, Access & Commercialization - Government and Hospitals and other major 
purchasers 
This section explores existing processes and structures of commercializing treatments and how 
these act as inhibitors to innovation. It outlines key needs and barriers for payers as they strive 
to improve health outcomes, healthcare efficiency while managing risk and promoting safety. 
•   The Clinical Trials Process – a description of the Clinical Trials process and the ways in 
which it protects health and safety, but also inhibits drug innovation.  
•   Paying for and Approving Digital Therapeutics – a description of some of the challenges 
faced by payers in leveraging the potential of digital therapeutics.  
•   The Cost of Personalized Therapeutics – a description of the cost inhibitors for 
pharmaceutical companies to commercializing innovative, personalized medicines.  
 
3. The Data Ecosystem - Tech, or tech enabled Health players  
The data ecosystem that connects individuals to other stakeholders involved in facilitating 
treatment decisions. This section explores the current state of the ecosystem and highlights 
where there are gaps and challenges  and opportunities for digital therapeutics in the future.  
•   Barriers and Potential for Digital Therapeutics – A discussion of the potential and 
challenges that are facing digital therapeutics.   
•   The Data Infrastructure is Fractured - Protocol and Real-World Evidence – an exploration 
of the current state of data infrastructure and how the broken aspects prevent the 
prevalence of pharma alternatives.  
•   Data Security & Ownership – A discussion of the current status of data security and the 
challenges that would need to be addressed to facilitate the next generation of cures.   
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4. Care Delivery – Patients and Clinicians 
With the other sections focusing on the systems, processes and infrastructure of the healthcare 
system, this section focuses on the ways in which these tensions come to life at the point of care.  
•   Challenges in Adapting and Adopting – a discussion of the processual challenges in 
adopting digital and alternative therapeutics in regular practise. 
•   Lack of Alignment Between Providers – this section highlights gaps in education and 
details the misalignment between need, understanding and innovation.  
 
Where is there evidence of the future in the present?  
1. Discovery - Pharma and risk adapted corporate players/funders 
This section explores how the process of discovery may be shifting and the directions it could 
possibly take in the future.  
•   Innovation in Precision Medicine -- This section explores how technology innovations 
are driving new approaches to treatment and care in the pharmaceutical industry.  
•   Leveraging Digital Technologies – This section explores current use-cases for digital 
technologies in pharmaceutical products.  
 
2. Payers, Access, & Commercialization - Government and Hospitals and other major 
purchasers 
In this section, the researcher will explore signals that point to a potential change in the way that 
reimbursement, commercialization and access may shift in the future.  
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•   Bedside Pharmacy – If successful, bedside pharmacy may have an impact on the way that 
drugs are manufactured and personalized for patients, disrupting the drug manufacturing 
process. 
•   3D Printed Drugs – 3D printing has the potential to radically change the way that drugs 
are manufactured and distributed by changing the supply chain, creating new 
opportunities for stakeholders outside of the pharmaceutical industry.  
 
3. The Data Ecosystem - Tech, or tech enabled Health players  
This section will explore signals that point to change within the data ecosystem and how this may 
create more viable options outside of pharmaceutical products.  
•   Disruption from Non-traditional Players – Stakeholders outside the bounds of 
conventional healthcare providers are beginning to enter healthcare and may radically 
shift the way that care is provided.  
•   Direct to Consumer Healthcare – This section speaks to the emergence of consumer 
healthcare products that are driven by data and may create disruption.  
•   Bypassing Biological Trials – New capabilities in AI and machine learning may enable 
researchers to simulate potential drug responsiveness, reducing financial barriers to 
generating clinical data and commercializing medicines.  
 
4. Care Delivery - Patients and Clinicians 
This section will explore potential changes in the way that care may be delivered and the ways in 
which perspectives and values in care may change given the shifts in the healthcare system.  
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•   Global Perspectives – A description of how the Chinese government is leveraging digital 
technologies to promote a preventative approach to care.  
•   Digitally Savvy and Empowered Patients – A description of how patients’ sense of 
ownership and responsibility may change in the future.  
 
THIRD HORIZON 
What’s the hopeful future?  
•   Better treatment – Leaders in healthcare are looking towards a future where better, more 
personalized treatments are available by any means necessary. This will include working 
with emerging stakeholders to facilitate improved, innovative approaches to treatment.  
•   More cost-effective system – Cost-effectiveness is a both a goal and necessity for a 
viable, sustainable healthcare systems in the future.  
 
1. Discovery 
This section explores the future of drug discovery and the delivery of innovations.  
•   Empowerment and New Channels of Discovery – New capabilities are creating hopes for 
a new model of drug discovery that would allow for new channels of discovery, and 
empowerment to create more discoveries outside of pharmaceutical companies   
•   Providers with time to provide care – The hopeful future is that care can be improved not 
only at the systemic level but at the provider level, where the impact is experienced by 
patients.  
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2. Payers, Access, & Commercialization - Government and Hospitals and other major 
purchasers 
The hopeful future for payers, access and commercialization is one in which medical treatments 
are more affordable, and accessible by more patients.   
 
•   Creating Equity – This section explores the hopes for improved access and equity of the 
quality in patient care.   
•   Affordable – In lowering the costs of care and making it more affordable, payers are 
looking for a means to create lower premiums to reduce the economic burden of care.  
 
3. Data Ecosystem - Tech, or tech enabled Health players  
This section explores the hopeful future for the data ecosystem that would facilitate open data 
networks and secured data for patients.  
 
•   Privacy & Openness – a key hope for the future is that future data ecosystems will be one 
in which privacy and openness are supported to allow for more access to information that 
would allow for more stakeholders to have the ability to innovate.  
 
4. Care - Patients and Clinicians 
This section explores the future of care and the ways in which more personalized treatments can 
be facilitated at the provider level.  
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•   Integrated Problem Solving – the ability to create possibilities for integrated problem 
solving and intelligence sharing is critical to facilitating the next generation of treatments 
and medical discovery.  
•   Caring for Chronic Diseases – the creation of models of care to both prevent and care for 
chronic diseases, has the potential to create a large impact in improving health outcomes, 
potentially shifting or relieving the reliance on medications.   
 
What’s worth keeping from the present?  
•   Protecting Primary Care – Given all the shifts in responsibility, capability and ownership, 
this section explores the importance of protecting and promoting primary caregivers in 
the wake of disruption and facilitating a means to be educated, and prescribe beyond 
pharmacological response.  
•   Data Transparency and Ownership – The increasing importance of data in the provision 
of care means that awareness needs to be placed on individual privacy and security for 
personal data. In addition, it requires advanced methods for sharing and opening data 
sources to create pathways for innovation.  
 
SECOND HORIZON 
How do we bridge the gap?  
Critical Tensions – Key tensions that emerged through the research that are likely to shape the 
direction of the future.  
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Scenarios – Short vignettes to bring to life some of the tensions and opportunities that may 
manifest in the future.   
Summary of Findings – A summary of key findings: Incentives, Risks and Opportunities for 
each stakeholder.  
Strategic Roadmap – A comprehensive set of recommendations directed at the pharmaceutical 
industry to continue to build resilient business models moving into the future.   
Conclusion – A summary of findings.  
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Data that Heals  
 
The pharmaceutical industry has long been a subject of contention. As a for-profit industry made 
up of monolithic organizations, histories of scandal such as the Thalidomide scandal of 1961, 
complex incentive structures and a virtual monopoly in the provision of drug treatments, many 
stakeholders within healthcare, government and consumers of pharmaceutical products have 
come to question whether the role that pharma plays in healthcare to a be one that is positive or 
negative.  
 
Recent advances in technological developments have led to an increased ability to capture, store 
and analyze data through the use of digital tools that combine digital devices and machine 
learning. The proliferation of data is currently outpacing scientists’ ability to leverage the data in 
a meaningful way. However, at some point this is likely to change. There are currently many 
companies that are working to create novel approaches to disease diagnosis and management that 
have the potential to reduce reliance on pharmacological interventions. The rise of chronic 
diseases has increased the cost of healthcare to a point that it is virtually unsustainable. It is 
estimated that by 2025, chronic diseases will affect nearly half of the American population. 
(49%). (Fightchronicdisease.org, 2018) Digital Therapeutics offer the potential for effective, 
cheaper alternatives that are targeted at areas that are not well addressed by the current 
healthcare system and pharmaceutical companies including chronic disease. (Joyce, 2018) 
 
Importantly, digital therapeutics tend to target conditions that are poorly addressed by the 
healthcare system today, such as chronic diseases or neurological disorders. In addition, they 
can often deliver treatment more cheaply than traditional therapy by reducing demands on 
clinicians’ time. And all the while, more evidence is emerging to demonstrate their value in 
clinical terms. (Joyce, 2018) 
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In the development of this report, the researcher reviewed trends, drivers and signals that may 
indicate a necessary change and capability of digital therapeutics to uncover areas of potential 
disruption for pharma. Through a thorough scan of technology and innovation magazines, health 
blogs, and newspapers, and review of records of contemporary discourse around health with 
respect to pharmacological interventions this report attempts to synthesize where there are 
changes and potential disruption to pharma by digital therapeutics and non-traditional players.  
  
This scan and literature review resulted in four key findings:  
  
1)     It was widely apparent that our current approach to healthcare delivery is no longer 
working. Much of care is suboptimal with unsustainable costs, and many treatments 
are ineffective and only add to existing healthcare challenges. 
2)     New technologies have the ability, for the first time, to provide a new level of 
precision. Our ability to collect many new kinds of data engenders hope that we will 
gain new understandings of the body and ways we may be able to heal it. 
3)     Personalization seems to be one advancement that could solve some of the 
inefficiencies of the healthcare system; the increasing availability of detailed data will 
make personalization a more effective process. 
4)    Innovation seems to be emerging from outside the realm of pharma R&D and is 
beginning to be led by technology companies. If data is truly the gateway to the next 
wave of treatments, pharma may not be best poised to lead treatment in the future.  
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Health outcomes are affected by more than available treatments. Health is also affected by 
provider decision-making and, of course, lifestyle factors. However, this report will focus on the 
opportunities that may come from focused use of detailed patient data in an effort to create more 
multimodal approaches to curing illness that extend beyond pharmacological approaches. It 
acknowledges and explores potential barriers, pain points and outlooks for pharma and risk 
adapted players in innovation. These same areas of vulnerability are also opportunities for 
emerging players from the technology sector to begin to play an increasingly large role in 
delivering care.  
 
This project is concerned primarily with the future of healthcare in North America. While the 
cost and payer negotiation process is different in the United States and Canada, the impact of 
pharmacological innovation is similar in both countries. Where there is a difference, the text will 
reference how this may affect the universal healthcare model (Canada) versus a privatized 
system (United States).  
 
Using the Three Horizons Model, this report will highlight the most powerful points of change 
occurring at the various levels of the system that expose why it is necessary for pharma to 
radically innovate, not only its products but business model in order to remain resilient moving 
into the future.  
 
This analysis is far from exhaustive; because of the breadth of signals taken into account, there 
are most certainly gaps. Further analysis may explain nodes of change at even deeper levels. This 
study is intended to provide a starting point; to present perspective on some of the big changes 
and to highlight opportunities for further investigation of specific areas. 
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The intention is to present the reader with a deeper understanding of how data and data capturing 
tools are democratizing the process of innovation in medical science. It will provide an 
understanding of how this may serve to disrupt pharma in the future.  
 
 
Summary of Findings from Literature Review  
 
The literature review, in combination with horizon scanning, created a theoretical scaffolding 
that will be carried through the rest of this report.  
 
First, in assessing the present and future state, it is important to look at four major groups of 
stakeholders that occupy four key functions in the medical treatment innovation system.  
 
1.   Discovery – Pharma and risk adapted corporate players/funders 
•   It is critical to understand (at least broadly) how drugs are developed and 
brought to market and how the current system has created innovation barriers 
for pharma and risk adapted corporate players/funders.  
 
As for-profit entities, pharma is incentivized to remain profitable and retain market control. 
In order to do this, they work to ensure exclusivity and access of their products, they attempt 
to secure and elongate profits from existing assets.  Pharma is faced with the tension of 
balancing the cost of innovation with potential for profitable outcomes, which acts as a 
barrier to innovation and reinforces the need to protect assets.  
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2.   Payers & Access - Government and Hospitals and other major purchasers 
•   Payers determine which drugs are made accessible, to whom and for how 
much. Within this category this report will explore how the economics of drug 
commercialization are creating innovation barriers for pharma.  
 
Government is interested in decreasing public expenditure on healthcare via improved health 
outcomes and affordable therapeutics. Private payers are similarly incentivized to improve health 
outcomes and efficiencies to increase profitability and lower payout costs. However, they face 
less risk as they’re able to pass through costs to the broader system. 
 
3.   Data Infrastructure & Ecosystem -  Tech, or tech enabled Health players  
 
•   New capabilities to collect, digitize, and integrate data are contributing to a 
shift in the way that treatments can be tracked, monitored and instigated, 
creating opportunities to create real world evidence to support drug efficacy 
and opening up opportunities for technology companies to play a significant 
role in the future of medical treatment.  
 
Technology companies are interested in clearing regulatory hurdles for digital therapeutics and in 
the meantime demonstrating potential use-cases for digital therapeutics to gain credibility, iterate 
to improve product quality and begin to attract investors and generate profit. 
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4.   Care/Treatment Delivery - Patients and Clinicians 
o   While the first three categories that will be discussed reference “back-end” 
aspects of the healthcare system, this section will explore how these tensions 
come to life at the point of care delivery.  
 
Patients and physicians are principally concerned with improving health outcomes and 
increasing the availability of affordable efficacious options.  
 
These sub-categories, while not an exhaustive list of stakeholders or structures within the system, 
will help shape the reader’s understanding of some of the major leverage points within the 
system to catalyze change or lead to disruption in the future.  
 
Secondly, the literature review exposed the deep, highly entrenched nature of the innovation 
barriers experienced by pharma. It has revealed that pharma may not be best poised to make 
significant shifts that will enable more access to better care. The current model has had both 
positive and negative impacts on society, but it is clear that the role of pharma in advancing 
science needs to be reconsidered.  If pharma cannot learn to better leverage data to create more 
effective, less harmful medicines, is it possible that non-traditional players may be able to play a 
disruptive role to bypass these challenges that are so entrenched in the current, risk-adapted 
system.   
 
 
Thirdly, the current paradigm of care is a primarily social and values-driven movement that takes 
aim at individualizing health as a way to improve outcomes, in a way that happens to be 
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intrinsically aligned with a neoliberal approach to health and care. This is not the only way or 
even necessarily the best way to improve health outcomes; this simply presents one perspective 
that is symbiotic with the pharmaceutical business model. As more treatment options become 
available, there may be a disruption to not only the way that diseases are treated but also a shift 
in values away from an individualized approach to one that is collective and preventative.   
 
Related concerns of Major Stakeholders: 
The stakeholder matrix below was developed for this report to show the interrelated concerns 
and incentives faced by some of the major stakeholders concerning the advancement of 
therapeutics. This should bring to light the tensions in the system which will be brought to light 
later in the report.   
 
Figure 5 – Stakeholder Matrix – Lindsay Roxon 
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These stakeholders have been grouped into the nodes of the system: Discovery, Access, Data 
Ecosystem, and Care. Each section will discuss the ways in which the stakeholder is incentivized 
to behave now and, in the future, and how this impacts their ability to innovate, disrupt and 
remain resilient moving forward.    
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First Horizon 
In the first horizon I will examine the current state of the medical system’s advancement toward 
precision medicine through the analysis of broad social, political, technological, economic, 
environmental, values trends and historical development that address the following subsections: 
What’s broken now? Where is there evidence of the future in the present?  
  
 This analysis will provide an overview of some of the larger forces at play in the medical system 
that are reinforcing, incentivizing a system that is unconducive to innovation and is vulnerable to 
disruption from emerging players. The intent of this Horizon is to understand a series of 
barriers, and the baseline from which we are currently working that will need to be addressed by 
the Second Horizon. 
  
According to Wendy Shultz, in a Three Horizons Analysis, the First Horizon is dominated by four 
key characteristics. 
  
First Horizon (H1) Characteristics from Wendy Shultz (Shultz, 2017): 
●      Today’s dominant patterns — accumulations of past decisions and designs 
●      H1 systems are fully integrated with surrounding culture “locked in” 
●      Well-established ways of dealing with problems frame approaches to new challenges 
●      Barriers addressed in the Three Horizons Analysis are typically dominated by 
quantitative sense of time as a limited resource. 
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 1.0.0 What’s broken now? 
 
The findings reported in this section are representative of the results of research conducted 
through a literature review and horizon scan. The sections below detail the innovation 
challenges that pharma is currently facing, and some of the ways that practitioners and 
administrators are attempting to address the gaps.  
 
Every day, millions of people are taking medications that will not help them. The top ten 
highest-grossing drugs in the United States help between 1 in 25 and 1 in 4 of the people 
who take them. For some drugs, such as statins -- routinely used to lower cholesterol -- as 
few as 1 in 50 may benefit. There are even drugs that are harmful to certain ethnic groups 
because of the bias towards white Western participants in classical clinical trials. (Schork 
609-611) 
 
 
1.0.1  Discovery 
The role of Pharma and risk adapted corporate players 
The pharmaceutical industry has evolved alongside the healthcare system. In order to capitalize 
on new capabilities in data proliferation to create customized medications and treatment plans 
and remain resilient in the face of emerging players, there are significant hurdles to overcome. 
The hurdles are largely systemic in nature, relating to the way our healthcare system, and 
specifically the knowledge gathering process, has evolved alongside the pharmaceutical industry 
in the 19th century.  
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The Drugs Don’t Work: Imprecision Medicine  
 
The evolution of Pharmaceutical Industry and Risk Adaption 
Over the last 150 years, formalized healthcare systems have developed around the world 
(Sheingold & Hahn, 2014). The structure, regulation and delivery of healthcare varies by 
country, but what is consistent is some understanding that health is of universal importance to 
both the state and individual.  The evolution, structure, and values of the formal healthcare 
system can be seen in parallel to greater societal and economic movements such as 
industrialization (Sheingold & Hahn, 2014).   
  
In the United States and Canada before the 1900s, healthcare was largely informal until 
economic and social influences drove the development of health infrastructure. These influences 
included the rise of accidents and injuries during industrialization and need to prevent 
productivity losses.  
 
In 1940, penicillin was brought to market, revolutionizing healthcare (Sheingold & Hahn, 2014). 
At around the same time there was an economic boom. In order to compete for workers, 
businesses began to offer health insurance to cover incidental costs of care. The Economic Bill of 
Rights introduced the concept of the right to appropriate medical care. While it still took decades 
for this to be represented in more tangible terms, it marks the beginning of a change in values 
that still persists today in most healthcare structures. (Sheingold & Hahn, 2014). 
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By the 1950s, the price of hospital care doubled with an explosion of new services being offered, 
including vaccines, medications, and organ transplants (Lawrence, 2011). The increase in 
complexity and rising cost of healthcare services made it very difficult for individuals to cover 
the cost of their medical care. As a result, non-profit insurance organizations began to form to 
help cover healthcare costs. This trend continued in the decades that followed, creating a 
dynamic relationship between the increased cost of care services and the specialization of those 
services. In the decades that followed, the United States’ economic growth facilitated rapid 
advances in medical science and discovery (Lawrence, 2011). 
 
In the 1960s, health insurance became unaffordable for many Americans, which led to the 
creation of the federal and state coverage for those who qualified: Medicare and Medicaid. In the 
1970s, as inflation rose, and new medical treatments and advanced surgical practices cost more, 
many people could not afford the premiums for basic health coverage through not for profit 
agencies (Lawrence, 2011). 
 
 With people living longer and receiving treatments that were continually increasing in cost, 
Medicare and Medicaid were no longer adequate to cover healthcare costs; this spurred product 
diversification in the insurance industry. There was an increase in privatization in order to 
manage costs (Lawrence, 2011). 
  
By the 1980s the complexity of the system and the variety of treatment options had nearly 
doubled the price of treatments. This trend continued into the 1990s, when medicine became 
more specialized, precise, and complex with the introduction of biologics. In the current decade, 
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healthcare costs are creating a burden on public systems and governments and can be largely out 
of reach of individuals in the United States.  
 
Pharmaceutical companies experienced tremendous growth over this time period as well, 
transforming from chemical and dye companies, apothecaries and chemists to drug production 
companies. This period saw the introduction of the world’s first blockbuster drugs (a 
pharmaceutical that reaches over one billion dollars in sales) and a series of lifesaving vaccines. 
However, after a number of pharmaceutical product scandals, government regulations were 
implemented to provide greater oversight of the drug commercialization process and make a 
clear distinction between chemical companies and pharmaceutical companies. 
The Thalidomide scandal of 1961 prompted an increase in the regulation and testing of 
drugs before licensing, with a new amendment to US Food and Drug Administration 
(FDA) rules demanding proof of efficacy and accurate disclosure of side-effects for new 
medications (the Kefauver Harris Amendment) being implemented in 1962. Likewise, the 
1964 Declaration of Helsinki put greater ethical strictures on clinical research, clearly 
cementing the difference between production of scientific prescription medicines and 
other chemicals. (Walsh, 2010) 
 
 
These regulations formed the foundation of the system on which pharmaceutical companies 
operate today. They illustrate a continuous tension in the healthcare system between innovation 
and risk aversion to protect the health and safety of patients.  
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Figure 6 -- Eroding Goals (adapted from William Braun “System Archetypes) (Braun 
2002) – Lindsay Roxon 
 
Fordian methods enabled more rational methods of mass production, and increasing 
understanding of biology and chemistry enabled drug candidates to be chosen 
systematically rather than discovered serendipitously. This ‘golden age’ of drug 
development took place in the broader landscape of the post-war boom, a general context 
of massive improvements in standards of living and technological optimism that 
characterized the 40s to the early 70s, as well as the science-boosting competition of the 
cold war. As the barriers to entry in drug production were raised, a great deal of 
consolidation occurred in the industry. Likewise, the processes of internationalization 
begun before the war were continued – in 1951 alone Pfizer opened subsidiaries in nine 
new countries. (Walsh, 2010) 
 
 
With new regulations in place, innovation became increasingly difficult as a result of the cost 
associated with commercializing drugs.   
 
But whilst there were some breakthroughs, the enormous expense and risks involved in 
R&D caused many to merely ape their competitors, trying to get a cut of market-share 
using “me too” formulations rather than innovating novel medications. For example, 
AstraZeneca’s popular proton pump inhibitor Nexium (esomeprazole), released in 2001, 
is merely a purified single isomeric version of an older drug which happened to be losing 
patent protection. Patents, or the lack of them, became a problem for the industry. 
(Walsh, 2010) 
 
The new regulations alongside the broader needs of society for generalized medicine, pushed 
pharmaceutical companies to pursue blockbuster drugs that would net their business over $1 
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billion in sales (Walsh, 2010). Many of these drugs were competitors, or copies of existing drugs 
that offered marginal benefits, but were already proven to have broad marketability (Walsh, 
2010). This acted as an inhibitor to pharmaceutical innovation; while there were significant 
strides made in the latter part of the 20th century in certain disease areas (especially cancer), the 
approach of marketing mass medicines continued (Walsh, 2010).  
 
The introduction of biologics, or complex molecule drugs that are derived from an organic 
source such as human, animal or microorganism in the 1970s led to breakthroughs in the 
treatment of more complex diseases like cancer and autoimmune disorders. However, the costs 
of these complex molecule drugs are creating major challenges for payers, especially as the 
incidence of chronic or lifestyle diseases (such as autoimmune disorders) continue to rise. This 
remains a major profit center for pharma, as these medications are more difficult and costly to 
replicate by generics companies while many other generic versions of previous single molecule 
drugs have been readily distributed in place of originator products.  
 
For a long time, there was little economic impetus for industry to market drugs solely to 
responders when its existing pharmacoeconomic models incentivized companies to sell as 
much drug to as many patients as possible, regardless of whether those receiving 
medication were responders or non-responders. By definition, commercial drug 
development is driven by the profit incentive as much as by whether patients fail to 
respond to a therapy. (Schellekens et al., 2017) 
 
 
The result of this is a system in which meaningful innovation is stifled; it encourages pharma to 
maintain a commercial strategy of pursuing the low hanging fruit of high profit, broad 
application therapies in order to maintain profits and deliver value to shareholders (Schellekens 
et al., 2017). While many pharmaceutical companies are continuing to invest in R&D, the 
likelihood of discovering a blockbuster has decreased, so pharma is being forced to leverage 
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other strategies to continue to encourage growth – including increasing prices and extending 
patents.  It also discourages the development of very niche or personalized treatments that would 
not have the desired return on investment.   
 
 
 
 
Figure 7 - Success to the Successful- Lindsay Roxon 
 
As they have continued to adapt to manage the risk in product innovation, the cost of innovation 
has increased.  
 
As this report will go on to discuss, the changes required to allow pharma to overcome 
innovation barriers and pursue the development of personalized products is difficult and costly, 
requiring a large departure from existing practices and a retooling of the entrenched systems. 
These barriers, if not addressed, may leave pharma vulnerable to disruption by emerging players 
32 
 
that are approaching disease management using data-based tools, devices and preventative 
methods that have the potential to be less risky.  
 
 
 
Barriers for Pharma in Innovating in Digital Therapeutics 
 
While aware of the opportunities in innovating in digital therapeutics, Pharmaceutical companies 
have been slow to invest because their R&D process is lengthy and costly. In addition, 
pharmaceutical companies are not currently equipped to take on a new process to innovate and 
research.  
 
“On average, it takes at least ten years for a pharmaceutical product to complete its journey 
from discovery to the market, and the average cost to shepherd it through this process is $2.6 
billion.5Digital-solution innovators move more quickly. Their devices require the latest 
technologies coupled with a user-centric, iterative design process, which means their R&D 
teams must adopt an agile approach, welcoming and incorporating fresh feedback on ever-
evolving user preferences. Approaching R&D in this way is a skill that many pharmaceutical 
companies would have to build in order to compete in delivering digital therapies.” (Joyce, 
2018) 
 
In addition to this, the profit incentive is not as attractive. Digital therapeutics are currently not 
protected by the same patent protection that pharmaceutical products have. Meaning that any 
innovation could potentially be copied by a competitor. While technology companies are built to 
continually iterate and sustain in spite of the nature of the competitive, unprotected environment, 
pharma in incentivized and structured to invest in protected, relatively secure, market-proven and 
protected assets. (Joyce, 2018) 
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“Another disincentive is the pharmaceutical model itself. In most countries, patents give drug 
manufacturers 20 years or more of protection from generic competition. Regulators do not 
afford the same protection to devices. Competitors can avoid infringing design patents and 
enter the market quickly by making incremental changes to the technology they use. Add to 
these factors the massive differences in manufacturing and distribution, and producing digital 
therapeutics starts to look very different from producing pharmaceuticals.” (Joyce, 2018) 
 
However, many pharmaceutical companies, recognizing the value and the likely future that will 
be disrupted by emerging players are beginning to consider partnerships with technology 
companies that are built to thrive and compete in the technology sector. (Joyce, 2018) 
 
For this reason, many, if not most, true digital-therapeutics companies have attracted at least 
one investor or partner from the sector. Roche, for example, recently purchased mySugr, 
which seeks to treat diabetes. In the long term, more pharmaceutical companies may well have 
their own digital-therapeutics lines. But in the short term, partnerships may be the most likely 
way forward, especially for digital devices that act as extension therapies by using data and 
patient engagement to offer insights into the effectiveness of those therapies. (Joyce, 2018) 
 
 
Pharma is seeking technology solutions that leverage and capitalize on their therapies like digital pills 
that encourage adherence and create value for patients and physicians by generating insights and tools 
that improve the effectiveness of their therapies. This however, is a small step into the potential that 
digital therapeutics and tools have to offer. (Joyce, 2018) 
 
 
1.1.2 Payers Access and Commercialization 
 
Government/Hospitals and insurance companies: 
 
Payors including government/hospitals and private insurers are principally concerned with 
ensuring that medicines are safe and effective. The process by which medicines are 
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commercialized and approved for public consumption was introduced as a means to ensure 
public safety and appropriate oversight of the pharmaceutical industry. However, this model is 
proving to be outdated now that all the low-hanging fruit of molecule production have been 
developed, and research and development (R&D) move toward more personalized medicines. 
This section will explore different facets of the process of drug commercialization which drives 
costs and inhibits innovation.  
 
The Clinical Trials Process 
 
Randomized controlled trials (RCTs) are considered the sine qua non of applied 
biomedical research. The objective evaluation of the benefits and problems associated 
with novel clinical interventions by directly comparing them with standard or sham 
(placebo) interventions allows claims to be made about the ultimate effectiveness and 
utility of those interventions. (Lillie et al., 2011, pp. 161-173) 
  
The purpose of clinical trials is to collect necessary data to validate the safety of a medication, its 
impact on quality years of healthy life and ultimately to justify public and private investment in 
drug reimbursement. This is determined by an algorithm that factors in quality of life, length of 
life, public healthcare expenditure, and cost of investment. The clinical trial is vital to the 
commercialization of any drug, as this data is used by the FDA to generate approvals for drugs to 
reach the mass market.  
 
The cost of running a clinical trial is in the billions of dollars: “on an average, the research and 
development journey of these new drugs that make it to market takes around 12 years and cost 
more than € 1.5 billion” (Fusi, 2017). However, the data generated at clinical trials is not always 
reliable.  
Conventional phase III trials involve thousands of people. The intervention being tested 
is often given at random to one group while another group receives a sham treatment, 
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such as a sugar pill or the standard treatment that physicians would give such patients. 
Because scant data are collected on factors such as genetics, lifestyles and diets, the 
results of these trials often indicate the need for yet another study to validate the 
effectiveness of the intervention among the apparent responders and to establish the 
underlying mechanisms. (Schork, 2015) 
 
In addition, trial design has been historically very limiting as trial sample groups are somewhat 
arbitrary; they may focus on a particular demographic and fail to achieve sufficient breadth in the 
study. That may misrepresent the data, thereby making it irrelevant for large portions of the 
population. 
Essentially, our understanding of biology suggested that treatments worked through 
common mechanisms that were set apart from random variation. This assumption was 
substantially correct for approaches such as cytotoxic chemotherapy that target generic 
disease mechanisms, and it enabled considerable progress to be made in treating cancer. 
Towards the end of the twentieth century, concerns arose regarding the potential 
inhomogeneity of therapeutic effects because of socio-political characteristics such as 
race or sex. Many clinical trials were designed and analysed to examine such differences. 
Although motivated by politics and social justice rather than scientific fact, only minimal 
changes were actually made to the design of such trials — which was probably 
appropriate given the weak biological basis for differences that can be attributed to these 
superficial characteristics. (Biankin, Piantadosi & Hollingsworth, 2015) 
 
 In some ways, providers are always searching for supplementary data to help with clinical 
decision-making and treatment planning. They essentially run their own trials with patients they 
treat, understanding that medications may not be safe or effective for every individual; 
physicians have few indicators to use in order to determine treatment efficacy beyond trial data.  
 
 
While scientific capability is widespread across academic research centers, start-up 
biotechnology companies, other private and public sector entities and independent researchers, 
the regulatory structures and associated costs required to commercialize a product make it very 
challenging to innovate and develop outside of the conventional structures of the pharmaceutical 
industry. In addition, many discoveries never make it to market because they fail at different 
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parts of the clinical approval process. This doesn’t always mean that they would not be effective 
for segments of the population, but may not reach them due to marketing environment, timing, 
and other factors. “Each year, there are only a couple of dozen new drugs licensed for use. But in 
their wake, there are hundreds of thousands of candidate drugs that fail to clear these hurdles” 
(Fusi, 2017).  
 
 
 In addition, while drugs are being developed they are also under patent protection, which further 
stifles innovation over the course of the 10-year drug development process by preventing other 
manufacturers from commercializing or developing the same compound. This is in addition to 
20-year patent protection. “New drugs, like other new products, are frequently under patent 
protection during development. The patent protects the salmon calcitonin sponsor's investment in 
the drug's development by giving them the sole right to sell the drug while the patent is in effect” 
(FDA, 2013). 
  
With the improved ability to collect and analyze patient data, there may be new, cheaper avenues 
for treatment validation and achieving clinical data. Clinical trials, as they are currently designed, 
are a principal contributor to the cost of drug development and discovery. They are also designed 
to generate data that will support public safety and efficacy on a broad scale rather than the 
identification of side effects and individual responsiveness. More precise and improved 
treatments provide an opportunity to make the healthcare system more efficient by increasing the 
efficacy of treatments and reducing readmission due to adverse events and side-effects. 
However, this value can only be realized if the systems of reimbursement, distribution, and 
commercialization are also retooled. 
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Generics  
 
Payers are typically focused on trying to keep costs manageable and treatment accessible by 
encouraging and incentivizing the use of generic brands, which are significantly more affordable. 
Innovation challenges and incentives for pharma are further exacerbated by their struggles to 
maintain profitability amid looming patent expiration and the resulting increase in competition 
from generics.  
 
The evolving payer initiatives to reward generic use have also led to the erosion of 
branded drugs. Payers are becoming more effective in their efforts to influence the way 
prescriptions are issued and dispensed by pharmacists (Tuttle et al., 2004). In response to 
rising healthcare spending, governments in developed economies are supportive towards 
generic production to keep costs under control and to make public health system 
sustainable. (Song and Han, 2016) 
 
 
However, this creates a tension in the system that encourages pharma to find legal loopholes to 
extend patents, further encouraging a strategic game of controlling market share through 
marketing and corporate strategy rather than focusing efforts on R&D and innovation.  
 
Patents are the primary tools that the research-driven companies use to establish and 
maintain their brands in the marketplace and provide a window of opportunity to enforce 
the exclusivity of the inventions. (Song and Han, 2016) 
 
 
With these tensions constantly at play in the healthcare system, pharmaceutical companies are 
incentivized to protect their products and extend patent protection. While this is a profitable 
strategy, it demonstrates pharma’s vulnerability to innovators entering the market. With the 
costly path to commercialization, protection rather than innovation remains the strategic 
imperative. With digital therapeutics gaining credibility, pharma could be vulnerable to 
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disruption, since pharma does not have strategic protection against alternative modalities 
including digital therapeutics.   
 
Paying for Individualized Medicine 
With a recognition that the “low hanging fruit” of molecule production has been captured, 
pharma is increasingly moving toward more individualized medicines or personalized 
medications that are customized based on genetic profiling. While this appears to be an 
opportunity, there are significant challenges in making individualized therapies (within the 
context of pharmaceutical products) viable and affordable. While there are ways to create more 
individualized medicines, the existing networks through which drug manufacturers can develop 
and commercialize drugs make it costly and ultimately inaccessible for the majority of patients 
and payers (Schellekens et al., 2017).  
In current reimbursement systems based on perceived value of a treatment, the limited 
markets for precision or personalized drugs will be similar to molecularly targeted orphan 
indications like lipoprotein lipase deficiency. This will drive up drug prices, rather than 
reduce them. (Schellekens et al., 2017) 
 
As more diseases are fractionalized and eventually understood at a unique level, the economics 
around treatment and care may be forced to undergo a large shift. A useful proxy may be to look 
at the ways in which molecules for orphan drugs or rare diseases are developed.  
In the few papers discussing affordability and cost-effectiveness, several solutions are 
suggested with the common theme being better collaboration between the diagnostic and 
pharmaceutical companies, regulators, funding agencies, payers and patients. However, it 
is difficult to imagine how such aspirational solutions will lead to cost control, 
considering the underlying causes of spiraling drug prices. (Schellekens et al., 2017)  
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There are 7,000 different types of rare diseases; almost 10% of the American population lives 
with a rare disease. ("Rare Diseases Foundation - The Ryan Foundation", 2018) It is estimated 
that 350 million people worldwide are living with rare diseases. As our understanding of disease 
becomes more precise we will continue to see a branching of types and subtypes of diseases 
considered common, such as breast or lung cancer; however, the current drug approval process is 
much too slow to accommodate the treatment needs of patients. ("Rare Diseases Foundation - 
The Ryan Foundation", 2018) 
 
It is estimated that 95% of all rare diseases do not have any FDA approved treatments, 
and there are currently less than 400 treatments approved by the FDA for the nearly 7,000 
rare diseases which have been identified. According to estimates from the NIH, it will 
take 10,000 years at the current rate of FDA drug approvals to find therapies for all 
people suffering from rare diseases. ("Rare Diseases Foundation - The Ryan Foundation", 
2018) 
 
 
Individualized medicines offer some hope for individuals who suffer from these diseases, but the 
economics are still quite challenging and may require a complete overhaul of the supply chain in 
order to make these approaches more sustainable.  
 
The current pharmaceutical system is far too complicated, expensive, time-consuming 
and inflexible to provide medications tailored to individual patients”, according to 
Schellekens. “In the second half of the 20th century, medications were generally 
developed for large groups of patients. Now that the patents for these drugs have expired, 
pharmaceutical companies are focusing on drugs to treat rare diseases and for specific 
populations, such as patients suffering from cancer or chronic illnesses. The prices for 
these drugs are exceptionally high; treatments that cost more than € 100,000 are no 
longer the exception. (Schellekens et al., 2017)  
 
 
While specialized molecules are privileged in the regulatory process in that they are fast tracked 
by the FDA, the research and development process and market sizes typically make the costs of 
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these drugs inhibitive. “Glybera is a treatment for a rare condition that causes pancreatitis. It 
costs $1.3 million for a single patient's full course of treatment” (Schellekens et al., 2017). 
Researchers and scientists are looking for other solutions to bring down the cost of personalized 
or precision medicine. The clinical trials and commercialization process is simply not designed 
for specialized or personalized medicine. The data collection process (through clinical trials) and 
the drug manufacturing and distribution process ultimately make specialized medication virtually 
unaffordable.  
 
Paying for Digital Therapeutics 
Payers looking at digital therapeutics are examining their potential to improve outcomes and 
efficiency of healthcare. However, there are challenges measuring and providing evidence for 
promised outcomes.  
 
“Private health insurers, for example, will want to know that covering a new therapy will offer 
clear improvement in quality outcomes. If it can lead to better management of conditions, help 
control adverse events of unmanaged chronic conditions, close gaps in care, and so on, then 
they will consider paying for it. The problem is proving measurable and material outcomes 
that are clearly tied to the new approach and can be captured by the insurer in an adequate 
time frame. Some of the chronic diseases targeted by digital-therapeutics companies fester for 
years before requiring costly treatment.” (Joyce, 2018) 
 
 
In addition, because chronic diseases are long-term and are often diagnosed many years after 
onset of the first symptoms, payers are struggling with how to reimburse these preventative 
measures when the return may be captured by a competing organization.  (Joyce, 2018) 
 
“The incentive for a payor to invest in any therapy to prevent diabetes, let alone a relatively 
new digital one, when the return is likely to be captured by another organization, could be low. 
Employer health plans or single-payor systems might be better targets for companies offering 
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digital therapies. Employers have a larger net in which to capture savings, as their incentives 
include protecting against productivity loss, which is influenced by absenteeism and employee 
morale. Meanwhile, single-payor systems, such as government schemes that provide 
insurance for life, absorb the long-term risks with patients and have an incentive to pay for 
therapies that might mitigate them.” (Joyce, 2018) 
 
In addition, with much of the opportunity for digital therapeutics in the chronic health space, the 
amount of time required to collect sufficient clinical evidence may also prove costly.  
 
There are significant hurdles and barriers to be considered to innovating for both pharma and 
digital therapeutic companies. With payors eager to reduce costs of care, they may be 
incentivized to find alternative approaches to clinical approval for digital therapeutics, which 
could create a significant threat to the pharmaceutical industry.  
 
 
1.1.3 Care Delivery 
Physicians and Patients 
 
Physicians are seeking tools to provide their patients with better care and are grappling with new 
technologies, yet there are challenges with consistencies between providers. Providers are 
looking for multi-modal treatment options that extend beyond pharmacological products in some 
cases, but there might barriers to insurance coverage. However, providers are eager to leverage 
tools to share best practices and to generate real world evidence for their clinics. They’re looking 
for more opportunities to leverage technology in a meaningful way to address issues as they 
arise. Patients and Physicians have the opportunity to gain significantly if there are additional, 
expanded treatment options. With the shift to more value-based models of care, physicians’ 
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services might increasingly rely on outcomes delivered. In this case they will be looking for 
opportunities to create and monitor impact more closely.  
 
Physicians act as an exposure point in the healthcare system. It is here that the tensions emerge 
and play out where it matters most — in the delivery of care.  
 
“[Physicians interviewed] also said that the direct relationship between a doctor and a 
patient, including close supervision, would make it easier to diagnose safety issues as 
they arise” (Schellekens et al., 2017).  
 
 
For this reason, it is important to look at how healthcare providers interact with the broader 
system to understand the motivations and constraints that will impact their ability to consider 
pharmacological alternatives in the future.  
 
Digital Tools Orientation to Providers 
 
Digital Therapeutics offer physicians an opportunity to be closer to their patient, and potentially 
deliver truly personalized care. However, while the potential for digital therapeutics is recognized, 
physicians exist in a system which incentivizes the use of pharmaceutical products over multi-modal 
approaches to care. The reason for this may be that digital therapies require additional education, 
analysis and insight generation.  
“Believers in the power of digital therapeutics think that one day prescriptions for apps will be 
as widespread as they are for pills. But for apps to be widely adopted, they will have to be 
oriented as much to the provider as to the patient. Many digital therapies currently require 
changes to provider processes. For example, if an app tracks dosage and patient-reported 
symptoms, a provider is usually expected to do something with the data produced. The data 
requires analysis, and analysis requires time. Where capacity is constrained, physicians can 
regard additional data as more of a nuisance than an aid.” (Joyce, 2018) 
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In addition to this, some digital therapeutics do not actually require a great deal of clinical 
intervention. These types of tools would essentially mean making themselves obsolete in certain 
cases.  
 
“Where general practice is private, or in public payor systems that contract to private 
providers, physicians might have less interest in shifting demand elsewhere or in 
recommending digital tools—such as Sleepio, a Big Health app that targets insomnia using 
cognitive behavioral therapy—that might disintermediate them. As Hames says, “Behavioral 
interventions can be very, very low clinical risk, and deliberately open up a new care pathway 
of delivery mechanisms that don’t necessarily require a doctor or health professional, and that 
instead can rely upon self-referral.” (Joyce, 2018) 
 
 
This creates a tension for physicians who might be looking for alternatives to pharmaceutical products 
but at the same time would like to maintain relevancy and regular contact with their patients.  
 
 
 Lack of Alignment Between Providers 
 
DNA testing has become increasingly useful in the detection and treatment of various 
conditions, including cancer, intellectual developmental delays, birth defects, and 
diseases of unknown origin, and the cost of genetic analyses has dropped even as the 
speed with which their results are delivered has risen. Nevertheless, for most people, 
genetic medicine is not yet delivering customized care.  ("The Problem With Precision 
Medicine", 2015) 
 
Innovations in medicine and early steps forward in medical innovation have been made by 
genomics companies like Illumina and 23 & Me that are working on creating databases of 
genetic data. In the emerging provider ecosystem, there is a distribution of ownership that 
includes biotech, technology, pharma, and other non-traditional players, including digital 
healthcare providers. These new providers of healthcare are distributed across the system and 
forging new models of care - in the rush for innovation these companies occasionally do not 
consult physicians in development of technology. These technologies are sold to physicians and 
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care practices as an opportunity to drive better outcomes in care. (Graber, 2015) The challenge is 
that while technologies that collect this data have the ability to play a functional role in 
diagnostics, there is little standardization to ensure consistency from company to company. This 
can be confusing for healthcare providers, who do not have the time or resources to analyze these 
differences and make an educated assessment of their value. (Graber, 2015) 
 
At the same time physician education is falling behind the capabilities offered by technology 
companies. This is best exemplified in new capabilities in gene testing. “As scientists continue to 
draw connections between DNA data and health outcomes, the problem of interpretability 
continues to grow. Many doctors are simply not qualified to make sense of genetic tests, or to 
communicate the results accurately to their patients.” (Graber, 2015) 
  
In the field of genetic testing, too few physicians are educated to understand and apply genetics 
technology.  (Graber, 2015) Genomics companies are attempting to fill the education gap by 
providing physician education themselves, which is seen as inherently biased and sometimes 
creates contradictions between companies. In many cases, these companies may not be subject to 
the same oversight as pharmacological companies, so they may tend to push infallibility of their 
products without sufficient evidence of their effectiveness in creating better diagnostic outcomes.  
 
The director of financial operations at a 500-plus bed institution said he sees physician 
recruitment as a first, essential step in preparing to deliver precision medicine. “You've 
got to have doctors who can specialize in it before you can really even get the patients in. 
You can say, ‘Hey, we want to focus in on [precision medicine].’ That's great, but until 
you have the physicians, that's the key. So, for now, our focus is recruiting the right 
physicians and getting them the tools they need to be successful. (Graber, 2015) 
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Still, physicians recognize the value that increased data (in this case genomics data) could add to 
their practice and improve their ability to apply precision medicine, and they are eager to engage. 
“In this race to offer more value, they are jumping the gun, in my opinion….” (Graber, 2015) 
 
Physician Action Bias 
  
One challenge with increasing the data available to make clinical decisions, and one that will 
continue to be a challenge as digital tools proliferate.  With the introduction of new technologies 
there has been an increase in physicians’ ability to detect abnormalities, but this hasn’t had a 
direct positive impact on health outcomes. 
  
Virtually every family in the country, the research indicates, has been subject to over-
testing and overtreatment in one form or another. The costs appear to take thousands of 
dollars out of the paychecks of every household each year. Researchers have come to 
refer to financial as well as physical “toxicities” of inappropriate care—including reduced 
spending on food, clothing, education, and shelter. Millions of people are receiving drugs 
that aren’t helping them, operations that aren’t going to make them better, and scans and 
tests that do nothing beneficial for them, and often cause harm.” (Gawande, 2015) 
  
 This trend may continue as more data is available, leading to more diagnoses of diseases and 
even more impetus to take action as a result of an increase in diagnostic testing. This is important 
to watch as any efficiency or value that is created by digital tool proliferation will rely on 
appropriate use (rather than overconsumption) of new tools. The system is set up in a way that 
incentivizes specialists to perform their craft. In addition to that, physicians are typically paid on 
a per-service basis rather than overall health outcomes. 
 
H. Gilbert Welch, a Dartmouth Medical School professor, is an expert on overdiagnosis, 
and in his excellent new book, Less Medicine, More Health, he explains the phenomenon 
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this way: we’ve assumed, he says, that cancers are all like rabbits that you want to catch 
before they escape the barnyard pen. But some are more like birds—the most aggressive 
cancers have already taken flight before you can discover them, which is why some 
people still die from cancer, despite early detection. And lots are more like turtles. They 
aren’t going anywhere. Removing them won’t make any difference. (Gawande, 2015) 
 
 
1.1.4 The Data Ecosystem 
Tech, or tech enabled Health players 
 
The virtual monopoly that medical centers like Mount Sinai now exercise over patient 
data will be smashed, and researchers will finally have the masses of genetic data that the 
medical breakthroughs of the future require. “Can we do better for human well-being if 
information is more broadly accessible, where you’re leveraging the mindshare of the 
entire planet to evolve the models of disease?” Schadt asks. “Absolutely.” This is 
medicine as math, not guesswork, and every disease—even stage 4 cancer—might one 
day be druggable. (Mark Warren, Wired Magazine, October 2016) 
 
A foundational requirement to create the capacity for digital therapeutics is the ability to track, 
store, and analyze data to generate personalized insights into patient health. We are currently 
living in a moment rich in information, with the ability to collect data from wearable, 
implantable, and ingestible devices, digital diaries and a plethora of data streams available from 
other sources. However, there are still significant hurdles to collecting and storing data in a way 
that is meaningful for providers and researchers to deliver on the promise of precision medicine.  
 
Achieving Differentiation From the Wellbeing Market 
Digital therapeutics companies are tasked with the challenge of establishing themselves as 
differentiated from the wellbeing market in the minds of consumers and providers.  
“Indeed, some apps have fallen foul of regulators because of unsubstantiated claims about 
clinical benefits, helping instill doubts about digital therapeutics in the minds of consumers 
and healthcare professionals alike. As Peter Hames, CEO of Big Health, a digital medicine 
company, says, “We are in what I would consider the ‘quack medicine’ era of digital medicine 
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and digital therapeutics, where there’s a huge morass of solutions with incredible variance in 
quality—and there isn’t yet an established set of criteria.” (Joyce, 2018) 
 
However there is significant opportunity to disrupt and innovate, once differentiation is established 
and approved. 
“For instance, the US Food and Drug Administration (FDA) recently approved a mobile 
application to help treat alcohol, marijuana, and cocaine addiction, citing clinical trials that 
showed 40 percent of patients using the app abstained for a three-month period, compared 
with 17.6 percent of those who used standard therapy alone1(see sidebar “What is the value of 
digital therapeutics?”).(Joyce, 2018) 
 
If this trend continues, it is likely to create disruption for pharma if they do not develop strategies to 
keep pace with the rate of technological innovation.  
 
Data Infrastructure is Fractured – Protocol and Real-World Evidence 
With this digital infrastructure in place, Schadt envisions a future in which more and 
more patients share not only their genomes but also medical and lifestyle information 
collected by monitoring devices like glucometers, blood-pressure trackers, and inhalers. 
The hope is that, ultimately, these increasingly sophisticated, increasingly patient-friendly 
tests will be so comprehensive that a patient’s microbiome can be regularly sequenced, 
their RNA frequently examined, and their blood cells constantly monitored for signs of 
trouble. (Warren, 2016) 
 
The infrastructure required to facilitate digital therapeutics includes biobanks, secure data 
storage, a means for physicians to access the data in real time, and an affordable means to extract 
it from patients. Electronic medical records are an essential starting point, which, as they 
currently stand in the U.S. and Canada, pose significant challenges to integrating data via 
Application Program Interface (APIs) as a result of HIPAA compliance and the cost of 
investment in technical infrastructure.  
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 In order to prepare providers to truly absorb the capabilities that health data may offer, 
healthcare organizations will need to implement Learning Health Systems (LHSs), and a means 
by which patients and can collect, own, and share their data. A LHS is a networked data 
infrastructure system that exists at and across sites that allow administrators, providers and 
patients to collect, store and analyze data.  
 
 
Learning systems are nearly ubiquitous across industries. “The capability to share data – and 
harness its potential to generate knowledge rapidly and inform decisions – can have 
transformative effects on complex systems that produce goods and provide services.” (Friedman 
et al., 2014) Healthcare systems in US and abroad have not yet transitioned through this 
transformation. “The LHS as a vision for an integrated health system “… in which progress in 
science, informatics, and care culture align to generate new knowledge as an ongoing, natural 
by-product of the care experience, and seamlessly refine and deliver best practices for continuous 
improvement in health and healthcare.” (Friedman et al., 2014) The base value of an LHS is to 
figure out what works best and to provide that knowledge to all major stakeholders in the 
healthcare value chain—clinicians, public health professionals, patients, and other 
stakeholders—to create feedback loops. This will have the added impact of creating a level of 
standardization in infrastructure that is critical to create data that may have clinical use cases. “… 
second, there is a lack of standardization of the collection, storage and analysis of large amounts 
of genetic, serological, histological and population data to enable patient stratification in clinical 
practice.” (Schellekens et al., 2017) Learning Health Systems enable physicians with “knowing 
what works, understanding why it works, learning for whom it works, and applying that 
knowledge to address patient needs…” (Friedman et al., 2014). 
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Further physicians, researchers and administrators face challenges with technological system 
integration to make the data actionable, insightful and easily integrated into existing EMR.  
 
Providers who outsource aspects of their precision medicine initiatives, such as using 
outside genomic sequencing or lab support, sometimes struggle more with data 
integration than providers who establish a supporting technology infrastructure in-house. 
That is because when physical samples are sent to an outside lab for processing, the 
report is often sent back to the provider as a PDF attachment. PDF attachments cannot be 
entered into EMRs as data points. Nor can they be integrated with clinical decision 
support tools.  (Graber, 2015) 
 
In order for the data to be truly valuable we must first have the technology in place to facilitate 
data sharing between patients and their providers and between providers to ensure continuity of 
care and accuracy of diagnosis.  
Data Security & Ownership 
 
The problem is getting these exabytes of genetic data. Turns out you can’t just walk up to 
people, millions of them, and say, “Your data, please.” You must first persuade them that 
you’ll only do good things with it and won’t let it fall into the wrong hands. (We do like 
our privacy.) You must then convince the medical centers and genetic companies that 
collect this data that, rather than hoard it for their own profit. (Warren, 2016) 
 
 
Of paramount concern to the facilitation of precision medicine is the need to ensure the security 
of patient data. This is of critical concern especially when considering highly sensitive health 
information such as genetic data. At the moment, patients are rightfully wary of sharing 
information with health providers, let alone researchers.  
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New entrants in the health space are beginning to contribute to the process of data creation. 
These new entrants include consumer technology data capturing companies like FitBit and Apple 
Health, specialized consumer products like 23 & Me, and larger genetic sequencing companies 
like Illumina. 
  
Genetic research companies that are working on creating vast amounts of genetic data, like 
Illumina, produce research and sell their findings to customers such as pharmaceutical 
companies, hospitals, and researchers. They, along with other biotechnology companies also use 
their findings to create a variety of products and services that may be marketed and sold directly 
to health consumers. Some is used to create direct-to-consumer products, like Illumina’s spin-off 
company, Grail, which is working on developing an at-home cancer testing kit.  
 
This industry is developing more rapidly than the average consumer can keep pace with. While 
the sharing of this data is critical to advancing digital therapeutics, it is also imperative that 
industry regulators protect patients by giving them ownership of their personal data making 
consumers more active stakeholders in the ecosystem so as not to repeat the mistakes of the 
pharmaceutical industry.  
 
With the existing barriers facing the pharmaceutical industry in addition and the evident 
increasing capability of digital therapeutics, it is clear that pharma must adjust their 
organizational strategies to remain resilient in the future.  
 
  
51 
 
1.2.0 Where is there evidence of the future? 
1.2.1 Discovery 
Pharma Innovation 
We are graduating from the century of the molecule to the century of the system. It’s how 
the neurons connect and form networks that creates consciousness and behavior, and it’s 
creates the care we want.  
— Atul Gawand 
 
Stratified Medicine 
 
In breast and lung cancer care there is a great deal of research that is helping scientists 
understand how genetic factors play into treatment compatibility. The science is still, however, 
incredibly imprecise; genetic markers may give practitioners a better idea of how to treat a 
patient but they still have a limited number of tools (drugs) to treat disease. However, without 
understanding the patient’s unique genetic composition and how genetic receptors play into the 
efficacy of a treatment, physicians are not yet able to create treatments that are truly 
personalized. A more appropriate term for the way that medicine is being practised today may be 
stratified medicine, and this is still only true for certain conditions. 
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Figure 5 – New Paradigm Shift in Treatment (Das, 2017) 
 
While stratified medicine is bringing providers closer to the ability to choose the most 
appropriate treatment plan for patients, it does not necessarily exist on the same continuum as 
truly personalized medicine. Stratified medicine relies on the logic of statistical significance 
based on isolated genetic factors, whereas precision medicine takes an integrated approach at 
diagnostics and treatment.  
 
“As a recent article in Nature noted, an estimated 90% of the conventional and top-
selling blockbuster medicines only work for 30% to 50% of patients. What is even worse 
is the side effects and adverse reactions caused by these imprecise medications, 
accounting for 30% of acute hospital admissions every year.” (Das, 2017) 
  
Challenges in efficacy create additional costs in the healthcare system as many patients have to 
continually try new treatment options as a result of adverse events or lack of efficacy. 
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Researchers are continuing to look for ways to develop and commercialize new treatments that 
are more effective for patients. However, there are forces within the healthcare system that are 
hampering progress and may prevent innovations in precision medicine.   
 
In order to remain resilient, pharmaceutical companies will have to continue to drive research 
into increasingly rare conditions and specialized molecules. Some researchers believe major 
policy changes will be necessary to ensure that pharmaceutical companies continue to innovate 
rather than simply swap assets and seek strategic loopholes to generate profits.  
 
If revenues can only be sustained by exploiting the legislative loopholes, companies 
willing to invest in the development of medicine will face a serious dilemma on a long-
term scale. Without proper policy intervention, the rise in patent challenges will not only 
shorten the effective market life, but also contribute to the dearth of high-risk and high-
necessity drugs. (Song and Han, 2016) 
 
With the loss of revenues from molecules coming off patent and the majority of the low hanging 
fruit having already been developed, it is likely that pharma will be forced to consider strategic 
alternatives that may include some push toward precision medicine, and “niche busters.” 
 
The “low hanging fruits” in drug development have been picked to a large extent 
(Williams 2011) and it is necessary to protect their revenue stream by measures other 
than unjustifiably abusing the intellectual property right at the expense of competition 
and public welfare (Glasgow 2001). Therefore, pharmaceutical companies are 
encouraged to focus on specialty drugs with low substitution potential by creating the so-
called “niche busters” (Dolgin 2010; Kakkar and Dahiya 2014). (Song and Han, 2016) 
 
Further, it is critical that innovations continue to occur beyond medication as more payers are 
switching to value based models that require pharma to substantiate real world outcomes over the 
long term to prove that real value and efficiency is being created by keeping patients healthy. For 
many diseases, this requires doctors to find a balance for the patients between lifestyle 
management and medication. 
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In future, most medicines will likely be paid for on the basis of the results they deliver 
and pharmaceutical companies need to pursue the path of “profiting together” instead of 
“profiting alone” by moving into health management space and to go beyond medicine 
(pwc 2009). (Song and Han, 2016) 
  
Pharma Leveraging Digital Technologies 
In addition to attempting to innovate in the realm of precision and personalized medicines, 
Pharma is looking to digital technologies to increase the efficacy of their existing products. 
Sensors and digital pills can be supplementary to a pill by encouraging adherence and generating 
helpful patient insights.  
“This is extremely important because if you’re looking you might have noticed silicon 
and software are the technologies that are transforming pretty much any industry that’s 
out there. We have an opportunity now for the pharmaceutical industry to embrace those 
kinds of tools, to build them into their drug products and create a whole new window of 
opportunity for innovation that leverages the entire library of drugs that already have 
been discovered. And that is probably one of the most important opportunities in 100 
years.” (Joyce, 2018) 
 
This is an area of opportunity for pharma to innovate and increase efficacy without radically 
disrupting their product base, however if these insights or technologies do not add significant 
value for patients and providers, they may not deliver on the value promised.  
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1.2.2 Payers, Access and Commercialization 
Government/Hospitals and Insurance Companies 
 “Truth in science can be defined as the working hypothesis best suited to open the way to the 
next better one.”  Konrad Lorenz 
According to OECD predictions, exceeding budgets on health spending remains an issue 
for OECD countries. Maintaining today’s healthcare systems and funding future medical 
advances will be difficult without major reforms. Public expenditure on health and long-
term care in OECD countries is set to increase from around 6 percent of GDP today to 
almost 9 percent in 2030 and 14 percent by 2060. (The Medical Futurist, 2018) 
 
 
The n-of-1 approach to medicine is the process by which a physician can determine the impact of 
treatment decisions on a single patient, share the results with other physicians, and then create a 
meta-synthesis of the data to determine efficacy and results of the process. (Lillie, 2011) 
  
With more widespread access to digital tools like wearable, implantable, and ingestible devices 
that can passively record patient data, it may soon be easier to facilitate n-of-1 trials that produce 
reliable, easily shareable results.  The FDA and other regulatory bodies are in support of the n-
of-1 approach, but the challenges of designing and facilitating these trials remains a persistent 
barrier.  
American Health Regulators, the Food and Drug Administration and National Health 
Insurance have tried to encourage the use of “n-of-1” trials despite the fact that these 
have been disparaged as merely anecdotal, and despite pharmaceutical companies 
positing that they are excessively expensive to run. However, proponents believe that n-
of-1 trials can create greater efficiencies in the healthcare system by obviating the long-
term costs of administering inappropriate treatments and interventions. (Kravitz et al., 
2014) 
 
In Schork’s paper "Personalized Medicine: Time For One-Person Trials" he states that “if 
enough data are collected over a sufficiently long time, and appropriate control interventions are 
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used, the trial participant can be confidently identified as a responder or non responder to a 
treatment.  Aggregated results of many N-of-1 trials (all carried out in the same way) will offer 
information about how to better treat subsets of the population or even the population at large.” 
(Schork, 2015)  
 
 
Schork cites the following ways that the clinical trial process could begin to initiate n-of-1 
trials:   
1) Exploit the diversity of health-monitoring devices  
2) Identify new health monitoring devices and identifying appropriate disease 
biomarkers, such as tumor DNA circulating in the bloodstream.  
3) Engender a cultural shift in regulatory agencies, pharmaceutical companies and at the 
clinic level. (Schork, 2015) 
 
 
Bedside Pharmacy 
In terms of healthcare economics as a whole, the main contributor to soaring costs is 
innovation in a market that is driven by what is offered, rather than by medical need. 
There is no reason to expect this dynamic to change, despite the advent of precision 
medicine. If economics are driven by fee-for- service rather than by medical need, there 
is no reason why existing models of precision medicine would alter cost-effectiveness.” 
(Schellekens et al., 2017)  
 
Given the constraints and challenges facing the pharmaceutical industry and healthcare providers 
in making precision medicine a reality, leading thinkers are looking to uncover ways to “retool 
the development and product of drugs so that they are as close as possible to the patient.” 
(Schellekens et al., 2017) Advocates of this approach argue that if “a treatment occurs in the 
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same legal entity as the production of a drug, no restrictive, expensive and time-consuming 
marketing authorization would be necessary” (Schellekens et al., 2017). This would mean that 
providers would have to have legal recognition as both providers and manufacturers. Bedside 
Pharmacy, also known as magistral production, would create an opportunity for certain types of 
drugs that have smaller markets to be more available for reasonable cost, while being well suited 
as a platform to develop new drugs.  
“The expertise for producing drugs should no longer be the sole domain of industry; 
indeed, many people with expertise in drug R&D are being dismissed by larger drug 
companies increasingly focused on clinical development and marketing. Perhaps such 
individuals could now be coopted to support magistral drug development in academic 
medical centers.” (Schellekens et al., 2017)  
 
Incentivizing Preventative care 
 
Payers are increasingly looking toward technology that incentivizes preventative approaches 
toward care. There are insurance companies like HealthIQ that offer cheaper premiums to 
individuals that make healthy lifestyle choices.  In addition, there is a recognition that more data 
may offer more clear avenues for people to receive improved insurance rates based on their 
lifestyle.  
Technologies that allow collecting and storing data and connecting systems make it 
possible to move from reactive care towards preventive and personalized care, and it will 
be more and more so in the future. The spread of electronic medical records, the 
connectivity of data systems and big data analytics help collect, store and analyze more 
and more health data. Moreover, piles of data will be augmented with information 
stemming from health sensors, wearables, and trackers – which enable data collection 
about lifestyle choices. (The Medical Futurist, 2018) 
 
There is a large incentive for insurance companies to continue to create offerings like this for 
their customers as it decreases their costs and acts as a value-add for healthy living individuals.  
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Bypassing Biological Trials  
 
For pharmaceutical products that have large sets of data available, researchers will soon be able 
to simulate the drug’s responsiveness through data analysis. If this is to be a viable alternative to 
clinical trials, this could radically disrupt the drug discovery process. Eventually this could mean 
matching individualized data with drug data to determine likely results and outcomes, reducing 
the cost of clinical trials and providing researchers with real time feedback on how to modify, 
augment and innovate for optimal outcomes. (Kurtzman, 2017).  
 
Researchers are also experimenting with microchips that “recapitulate the microarchitecture and 
functions of living human organs” that will allow researchers to simulate a biological response to 
drugs. At the moment these are aimed at replacing the animal testing phase of a molecule, but 
eventually it could replace more advanced stages of the trials process. This again may lead to 
lower costs for clinical trials, which could reduce the cost for pharmaceutical innovation and 
make it more affordable for pharma to pursue “niche busters” and personalized medicines.  
 
 
3D Printed Drugs 
 
Facilitating truly personalized medicine may require a retooling of the drug manufacturing 
process.  3D printing technology innovations may eventually enable reproduction of single 
molecule drugs that are customized for patients.  
Additionally, a doctor or a pharmacist would be able to use each patient’s individual 
information — such as age, race, and gender — to produce their optimal medication 
dose, rather than relying on a standard set of dosages. 3D printing may also allow pills to 
be printed in a complex construct of layers, using a combination of drugs to treat multiple 
ailments at once. The idea is to give patients one single pill that offers treatment for 
everything they need. (Borukhovich, 2018) 
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These 3D printed drugs may enable new mechanisms of action that are currently not possible 
with mass production techniques. The implications for this are wide and varied and would create 
a new supply chain that would extend manufacturing into new arenas such as pharmacies and 
hospitals, and eventually homes requiring education and resources to manage this new dimension 
of drug delivery.   
 
Drug release profiles explain how a drug is broken down when taken by the patient. 
Designing and printing drugs firsthand make it much easier to understand their release 
profiles. 3D printing makes it possible to print personalized drugs that facilitate targeted 
and controlled drug release by printing a binder onto a matrix powder bed in layers. 
(Borukhovich, 2018) 
 
 
3D printing would eliminate the need for animal testing by allowing researchers to test drugs on 
imitation human tissue and increase the manufacturers ability to iterate on drug design quickly. 
While the new capabilities and implications that may be facilitated by 3D printing are still very 
much in the discovery phase, pharmaceutical companies like GSK are committed to exploring 
the technology’s new potential. (Goulding, 2018) 
 
1.2.3 The Data Ecosystem 
Disruption from Non-traditional Players  
It is currently challenging for players outside the pharma or biotech space to invest in and 
develop products, simply because of the cost of testing and validating products through the 
clinical trial process. With the emergence of digital tools such as wearables, it is becoming easier 
for non-traditional players to collect sufficient data to prove the efficacy and safety of their 
medical interventions.    
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In the race to develop more cures and accelerate research, the clinical trial process plays a crucial 
role. As more treatment types emerge and data devices become more easily accessible, there may 
be an opportunity to disrupt the way clinical trials are run, allowing other players to prove their 
drugs’ efficacy and gain market traction as physicians prescribe those drugs. 
 As more data becomes available by clinically approved devices, genetics companies, health 
platforms and other sources, doctors may be able to prescribe non-molecule based treatments 
with proven health outcomes, including digital medicines and lifestyle changes, to achieve 
targeted results. Only once this barrier is broken will it be possible for truly personalized 
medicine to be practised.  
 
Companies like Evidation Health are finding ways to generate clinical data for tools designed to 
prevent illness or create behaviour change to gain clinical approval.  
At the same time, a Swedish nuclear physicist was able to generate enough data to gain clinical 
approval to have a birth control app approved as a contraceptive (Berglund, 2017). It is as 
effective as the birth control pill but uses only algorithms to modulate behaviour. 
  
Due to regulatory hurdles, many companies are more likely to work towards providing digital 
tools that support wellness before trying to prove their clinical value. For this reason, there are 
many tools available, including 23 & Me, which focuses on providing its customers with data to 
help them identify conditions they may develop at some point in the future. As capability 
continues to grow, the applicability of these tools in clinical settings is likely to increase as well.  
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1.2.4 Care 
Prevention Strategies in China 
“With nearly a fifth of the world’s population in China, there’s plenty of data out there, 
but little is collected or organized in a way that can be analyzed. This has made the 
Chinese government focus on accelerating the roll-out of the disease-based standard 
clinical data repository across a range of therapy areas.” (Ho, 2017) 
 
The Chinese government is working to prove the viability and impact of prevention strategies. 
Their approach relies heavily on digital therapies and devices. (Ho, 2017) As a result of 
undersupply of healthcare workers, overcrowding of some of the country's most sophisticated 
hospitals, and poor access to healthcare, healthcare costs in China are becoming unmanageable. 
The Chinese government is launching an initiative to move the country away from a disease-
centered approach to care and move towards one that they are calling “big health” which aims to 
“deliver a full suite of health services that cover the entire care continuum with an emphasis on 
health management and chronic disease management.” With 62% of the Chinese population 
surveyed believing that Healthcare Professionals (HCPs) should focus on prevention, there is 
broad public support to push this movement forward. The goal is to have three, well established, 
digital national databases that incorporate health information, health profiles, and medical 
records by 2020. The Chinese government is also looking to smart devices and wearables to 
continuously collect health and contextual data with the intention of reducing readmissions, and 
facilitating more rapid emergency response and more immediate care to “avoid deterioration or 
adverse events, such as stroke or falls.” (Ho, 2017) 
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The Emerging Patient Archetype – The Empowered Patient  
 
In a future where devices to track and collect personal health data are readily available, a new 
kind of patient archetype is set to emerge. The patient of the future that is empowered with their 
own data and education may shift the orientation of the patient-physician relationship. 
 
Evidence of this is seen in emerging cases of patients that are leading the treatment or diagnosis 
of their conditions. A particular instance of this occurred with Dr. David Fajgenbaum, a former 
medical school student who developed symptoms of a rare disease. Unable to rely on routine 
treatment plans or medications, he was treated by a team of specialists who sought to uncover the 
mysteries and potential treatments for his condition. (Thomas, 2017) 
  
In Dr. Fajgenbaum’s case, he related to other doctors as consultants, and took full ownership of 
his condition, and became the primary expert of his condition. (Thomas, 2017) A data-fueled 
patient-centric system may operate in the future, where digital therapeutics make up a portion of 
a patient’s treatment plan may increase incidences of patients leading care. Creating more 
opportunity for self-management and self-learning may create less reliance on traditional 
pharmaceuticals and decrease the impact of pharmaceutical marketing efforts.  
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2.0.0 Third Horizon 
 
The Third Horizon expresses imagined futures and emerging changes. It highlights the 
transformative shifts from the present, exploring a broad range of future possibilities that could 
emerge. This section surfaces questions underlying cultural assumptions.  
 
2.1.0 What’s the hopeful future? 
 
It does little good to forecast the future of semiconductors or energy, or the future of the 
family (even one's own family), if the forecast springs from the premise that everything 
else will remain unchanged. For nothing will remain unchanged. The future is fluid, not 
frozen. It is constructed by our shifting and changing daily decisions, and each event 
influences all others. Alvin Toffler, The Third Wave 
 
____________________________________________________________________ 
 
 
“If we combine all these emerging technologies, if we focus them and make sure that the 
connections are made, then the possibility of discovering new cures, the possibility of 
applying medicines more efficiently and effectively so that the success rates are higher, 
so that there’s less waste in the system ... the possibilities are boundless.” — former U.S. 
President Barack Obama 
 
“You have to create a system where you have the patients’ permission to follow them 
throughout their lifetimes so that you can define the populations for whom a particular 
technology or treatment is beneficial.” — William S. Dalton, Ph.D., M.D. CEO, M2Gen, 
Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center 
 
 
The future is created by our collective conceptions of how it might look; our goals and 
conceptions of how far we can push the future forward. In order to gain some understanding of 
future trajectory, this section presents viewpoints on the future as expressed by some of the 
world’s influencers in technology, innovation, and medical science.  
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CEOs Discuss The Future of Health Care (Robert Reiss, Forbes Magazine, July 24, 
2017) 
 
Robert Reiss: What word codifies the potential future of healthcare? 
  
Sandra Fenwick: Precision medicine. I think we are on the cusp of some of the greatest 
opportunities for transformation in diagnosis, treatment and disease prevention. Now we 
are able to literally go into the disease-causing gene, modify it and either change the 
course of that disease or cure it. This is game changing! 
  
Paul Kusserow: Personalization. Personalized care planning when combined with 
behavioral economic principles drives engagement. When you look at it a lot of issues in 
health care, they are actually behaviorally driven, which means they are potentially 
preventable. I think it’s 80 percent of all health care could be cured or avoided if people 
changed their behaviors and habits. Once people are responsible for and own their care 
management and compliance, they can positively impact their own health. 
  
Brandon Carter: Customization. Data and digital platforms can match products and 
services to customer needs. For example, health care customer relationships can start to 
look like banking relationships where customers can swipe their card and health care 
companies will know if the customer has made a healthy choice. Just as banks incentivize 
their customers to use their cards for cashback or rewards on purchases, this technology 
could be used at supermarkets, restaurants, and health facilities to enable healthcare 
companies to create incentives for customers to live healthier. 
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We are at a point in time where we are beginning to see the edge of the next horizon in health 
care. This, for many, means curing, preventing and managing the majority of physiological 
diseases. We seem to be in the midst of a societal movement that extends beyond the traditional 
parameters of the medical field to leverage our current technology, ability to collect data and 
quantify the body towards the goal of generating breakthrough knowledge that will enable us 
reach this goal, but we’re not there yet. What remains to be seen is how much of the value of 
these discoveries is realized and how we’re likely to access these technologies in the 
future.  However, the push towards this holy grail will continue to guide us towards this goal.  
 
In a lecture at University of California, San Francisco, Mark Zuckerberg asked “Can we cure, 
prevent or manage all disease by the end of this century?” His question was apt, in that it 
articulated the aspirations of visionaries, and this sense that it is not out of the realm of 
possibility that we might do so (Letzter, 2016).  
 
The goal of the future of medicine, specifically Precision Medicine, is to create the possibility for 
patients to receive “the right drug, at the right time, for the right patient.”  The vision is that more 
diseases will be prevented and managed through lifestyle and social indicators, and for more 
complex diseases that will require a pharmacological response, there will the capability to 
personalize and customize treatment options that would optimize outcomes and minimize side-
effects. 
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2.1.1 Discovery 
 
Providers With Time to Provide Care 
Precise treatments that take into account the individual’s context and lived history require not 
only a means to collect data but also a reliable means to analyze and interpret that data.  
  
With this digital infrastructure in place, Schadt envisions a future in which more and 
more patients share not only their genomes but also medical and lifestyle information 
collected by monitoring devices like glucometers, blood-pressure trackers, and inhalers. 
The hope is that, ultimately, these increasingly sophisticated, increasingly patient-friendly 
tests will be so comprehensive that a patient’s microbiome can be regularly sequenced, 
their RNA frequently examined, and their blood cells constantly monitored for signs of 
trouble. Mark Warren, Wired Magazine, October 2016 
 
This can be done by individuals, professional and family caregivers, or physicians in this 
analysis. For the time being, the best representatives we have to play this role are medically 
trained professionals, or providers who have some education.  In order to allow them to 
capitalize on the findings, the system must change in such a way that gives providers more time 
to spend interpreting the results and translating these to better care for patients.  The depths of 
these insights may allow physicians not only to improve health outcomes for today but also make 
way for the possibility that we can prevent diseases from developing in future generations as 
well.  
 
2.1.2 Payers, Access and Commercialization 
 
 
Equity 
 
One of the major concerns with advancing precision medicine is the level of gross inequities it 
could cause. While the possibilities are inspiring on an individual level, there is concern that not 
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everyone will have access because of higher costs of individualized treatments before the 
production of such treatments reach an economy of scale that makes them more readily 
available.   
We have single gene tests, which are covered. But it’s still very hard to realize that 
reimbursement,” Moeckel said. The hospitals regularly have to negotiate patients’ 
coverage on their behalf. Oftentimes, tests will be bundled into existing packages so 
there’s no option for direct or additional reimbursement. Juliet Preston, MedCity News, 
May 2017 
 
 
Leading thinkers like Moeckel are already trying to get ahead of this trend by facilitating 
necessary public support for public solutions — mandatory health insurance, government support 
programs, etc. — and innovation approaches to disseminating the benefits of new discoveries to 
marginalized populations.  
Precision medicine’s aim is not to optimize the health of one individual. It seeks to 
systematically shift the entire medical practice and improve outcomes on a population-
wide scale. One by one. Whether socioeconomic factors are a part of this new paradigm, 
or simply a barrier to its implementation, there’s no getting around their existence. Which 
is why we need organizations like Dignity Health to realize the precision medicine dream 
— in its entirety. Juliet Preston, MedCity News, May 2017 
 
 
This focus on creating equity around the world — especially in the United States — is a unified 
vision, and perhaps even an imperative. Former President Barack Obama expressed the 
importance of this after launching the Precision Medicine initiative in 2016: “Democracy can’t 
function if you have 20% - 30% of the population living longer than anyone else.” He went on to 
discuss why investment in supportive public infrastructure was critical to meet this goal.  
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2.1.3 Data Ecosystem 
 
 
Privacy & Openness 
 
 
One of the defining factors that will shape the future is how data is shared, owned and protected. 
One hope for the future is that new technologies like blockchain will provide long-term security 
to patients who are willing to volunteer their information for public use. While many people 
currently share private information openly with technology companies in exchange for access, 
neither company policies nor user expectations are clear. Many companies are building profit 
models built on an expectation that users will share private information in exchange for access; 
consumers should be empowered to control how their data is used.  
 
While data-based healthcare offers many opportunities for patients to become more active 
participants in their healthcare — with giant monoliths like Illumina already dominating the 
genetic data market — we’re at risk of repeating mistakes of systems-past that favour corporate 
monopolies that minimize the rights of patients. This is especially hazardous in the healthcare 
environment where access may be perceived to be critical to survival. 
 
In order to facilitate precision medicine in a way that is accessible and equitable, it is critical that 
data is owned by individuals and that there is safe and secure means by which they can share that 
data anonymously. It requires that organizations remain collaborative in sharing data and that 
payers find ways to provide equal access.  
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2.1.4 Care 
 
Creating Opportunities for Collaborative Problem Solving 
 
“The only time that a physician and physicist get together is when a physicist gets sick.” 
Malcolm Gladwell 
Priscilla Chan and Mark Zuckerberg have launched the Chan Zuckerberg foundation with the 
lofty goal of eradicating all disease within this century (Letzter, 2016).  
 
The three objectives of the foundation’s initiative are:  
•   To foster collaboration between teams of scientists and labs across multiple 
universities over long periods of time. 
•   To focus on developing tools that are geared toward eradicating diseases rather than 
simply treating them. 
•   To improve and expand scientific funding writ large.  
There is a recognition of three major challenges in their objectives: 
1.    the need for improved approach to funding and commercialization; 
2.   the need for increased efficacy of drugs; and  
3.   the need for more collaborative decision making and problem solving within medicine.  
As new, non-traditional providers disrupt the healthcare ecosystem, bringing with them the 
philosophy and ethos that dominates the technology sector of failing fast, empowering 
consumers and creating human centered experiences there may be changes to the way that 
healthcare problems are solved. It is the need for collaborative approaches to solving problems 
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that may start to dominate the practise of decision-making in healthcare. This is critical; we seem 
to be at a moment in time where there is great need and great potential. Yet, this will be 
dependent on the ability of major stakeholders in the health ecosystem to collaborate, share 
knowledge and create novel approaches to solving some of the greatest challenges facing 
healthcare today.  
 
2.2.0 What’s worth keeping from the 
present? 
 
With the diversification of healthcare options – it is critical that there remain mediators built into 
the system and that patient rights are protected and evolved to include broader definitions of 
data.  
 
2.2.1 Protecting Primary Care 
 I noticed other patterns in Bordone’s interactions with her patients. For one thing, they 
almost always left feeling better. They had been touched and scrutinized; a conversation 
took place. Even the naming of lesions—“nevus,” “keratosis”—was an emollient: there 
was something deeply reassuring about the process. The woman who’d had the skin exam 
left looking fresh and unburdened, her anxiety exfoliated. ("A.I. vs M.D.", 2017) 
  
It is critical that as the organization of healthcare teams begins to shift, providers continue to 
provide patients with a single point of contact. This has two benefits: on the one hand, it ensures 
high quality service to patients; and on the other, it keeps physicians in touch with real world 
evidence.  
The chain of discovery can begin in the clinic. If more and more clinical practice were 
relegated to increasingly opaque learning machines, if the daily, spontaneous intimacy 
between implicit and explicit forms of knowledge—knowing how, knowing that, 
knowing why—began to fade, is it possible that we’d get better at doing what we do but 
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less able to reconceive what we ought to be doing, to think outside the algorithmic black 
box?. ("A.I. vs M.D.", 2017) 
 
If physicians are removed from aspects of the health continuum, it would be more challenging 
for them to assess broader pattern recognition. Smaller symptoms of seemingly simple ailments 
could actually add up to more complex health challenges that physicians are experts in 
interpreting. 
A deep-learning system doesn’t have any explanatory power,” as Hinton put it flatly. A 
black box cannot investigate cause. Indeed, he said, “the more powerful the deep-learning 
system becomes, the more opaque it can become. As more features are extracted, the 
diagnosis becomes increasingly accurate. Why these features were extracted out of 
millions of other features, however, remains an unanswerable question. The algorithm 
can solve a case. It cannot build a case. ("A.I. vs M.D.", 2017) 
 
 
2.2.2 Data Transparency & Ownership 
 
There is a growing movement to shift the balance of data ownership to individuals over 
organizations. This exists at the tension of making data pools increasingly transparent and open 
to encourage research and insight development.  However, there is always a risk of over-
regulation of data, which could put insight development in peril.  
 
A balance must be struck between an individual’s desire for privacy and their desire for 
good evidence to drive healthcare, which may sometimes be in conflict. Opportunities for 
research on EPR and public health medical datasets have already demonstrated 
impressive results in generating new evidence (2); however, new computer science 
approaches analyzing real-time Big Data streams generated by social media and 
increasingly popular tracking/wearable devices have re-charted the data ownership 
landscape. (Kostkova et al., 2016) 
 
Increased security and advanced thinking around the regulation of data could have a significant 
impact on the way data is integrated and leveraged in healthcare for the purposes for precision 
medicine in its ideal form.  
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The potential of opening healthcare data and sharing big datasets is enormous – but the 
challenges and barriers to achieve this goal are enormous. As transparent access to Big 
Data is the key challenge for healthcare research on clinical and population research 
datasets, policymakers, and scientific and business communities should embrace the 
underlying challenges of a political and legal nature. (Kostkova et al., 2016) 
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3.0.0 Second Horizon: 
The Second Horizon provides an opportunity to look at both the past and the future – in it, 
designers may consider possible solutions, recommendations, and areas for further research that 
would help bridge the gap. In this section, designers may begin to grapple with areas for 
innovation and the potential trade-offs that may have to be managed in order to solve problems 
highlighted in the first horizon.  
 
3.1.0 How to Bridge the Gap 
 
Moving to a healthcare system in which precision medicine is possible is a massive undertaking. 
Key aspects of the healthcare system must evolve in order to facilitate the possibility of 
delivering the right treatment, at the right time, for the right patient. Especially prevalent is the 
need to rethink the design and focus on a healthcare system that currently places a large focus on 
pharmaceutical products that are limited in their ability to act as effective ‘cures’ to diseases as a 
result of barriers in the pharmaceutical innovation process.  
 
This report examined the ways in which precision medicine is being inhibited by existing and 
entrenched systems related to the regulation and practice of producing and distributing 
pharmaceuticals. Specifically, this study looked at pharmaceutical products which are a major 
contributor to the increasing cost of healthcare. This section will hypothesize potential solutions 
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and strategies to facilitate the next generation of medicine, which moves away from an 
industrialized approach to one that is individualized. 
 
With rising healthcare costs, an aging population and mass inefficiencies, it has become evident 
that a change needs to occur. For most major stakeholders that are concerned with 
revolutionizing healthcare, there is a recognition that reducing inefficiencies and improving 
quality of life lie in the ability to create treatments that are more effective and personalized to an 
individual’s health context and preventing illness before it starts. Both prevention and 
personalization require improved ability to understand health implications and improved health 
management on an individual level. Fortunately, we are at a moment in time that offers an 
abundance of new technologies and scientific advancement that could have a major impact on 
the way that treatments and the delivery of those treatments are improved. Facilitating these 
treatments will require a multipronged, long-term investment in a unified vision of precision 
medicine and the investment in the technologies, capabilities and processes to ensure that this is 
happening at every level in an equitable way.  
 
 To better compare the research findings, a 2x2 matrix was created to demonstrate the differences 
in how differing visions of the future may drive different trajectories across the continuum of 
possibilities. The purpose of the matrix is to highlight the extremes that might exist at either end 
- in reality, at any given point in time, multiple ‘futures’ coexist across different geographies, 
political environments and institutions.  
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There will likely be a cross-section of the possibilities highlighted in the matrix that exist at one 
point in time, however, where this becomes useful is identifying how dominating stakeholders 
might operate in order to ensure their continued survival, and where this may cannibalize 
resources away from other efforts at investment. For stakeholders outside of pharma, this may 
reveal opportunities for policy shifts, technology investment etc. In fact, this might reveal that 
the pharmaceutical industry may not be best poised to lead the movement towards precision 
medicine.  
 
Specifically, this will look at two critical tensions which have emerged from the research, 
individualization versus collectivism and pharmacological versus diversity in treatments.  
 
Critical Tensions 
 
Individualization: The individualization of society and resultantly, of healthcare, has been 
guiding an increasingly accepted view that individuals are responsible for their own health. New 
technologies such as wearable devices, while helpful to track individual fitness, diet and other 
behavioral aspects of health, are an example of a shifting of responsibility from the collective to 
the individual.  
In short, “neoliberalism” is not simply a name for pro-market policies, or for the 
compromises with finance capitalism made by failing social democratic parties. It is a 
name for a premise that, quietly, has come to regulate all we practice and believe: that 
competition is the only legitimate organizing principle for human activity. (Metcalf, 
2018) 
 
Pharmaceutical companies operate at a juncture in healthcare that is inherently collective and yet 
also a beneficiary of individualistic approach to medicine. If individualism continues to guide the 
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development of our system it may eventually provide pharma with an opportunity to bypass 
government all together and sell directly to health consumers.  
 
Thirty years on, and it can fairly be said that Hayek’s victory is unrivalled. We live in a 
paradise built by his Big Idea. The more closely the world can be made to resemble an 
ideal market governed only by perfect competition, the more law-like and “scientific” 
human behaviour, in the aggregate, becomes. Every day we ourselves – no one has to tell 
us to anymore! – strive to become more perfectly like scattered, discrete, anonymous 
buyers and sellers; and every day we treat the residual desire to be something more than a 
consumer as nostalgia, or elitism. (Metcalf, 2018) 
 
 
Collectivism: A collective approach towards healthcare is one that values and structures systems 
that facilitate collaborative approaches towards public health, that highlights the 
interconnectivity and social nature of health. A collective approach requires a central governing 
body (like government) to coordinate and regulate strategies and health systems. Examples of 
this can be seen in China, where the state government is focusing efforts on more preventative 
measures by encouraging the use of digital tools to help manage lifestyle disease factors and care 
for chronic diseases.  
 
Pharmacological Carel: The last 50 years have seen increasingly close ties between the medical 
industry and pharma. Moving into the future, the ways in which those ties are either endorsed or 
opposed by public policy will impact the way that innovations in precision medicine come to 
life.  
 
Over time, this casual alliance has been reinforced with such complex and often invisible 
bonds that, in Dr. Brody’s title metaphor, medicine and pharma are now “hooked” like 
two pieces of Velcro, tethered by a million barbs and as dependent on each other as any 
addicts are on their substance of choice. 
 
77 
 
The ways in which this relationship progresses will determine the way that precision medicine is 
shaped and delivered in the decades to come.  
 
All this mutual back-scratching would be fine if patients’ interests were indeed being 
served. But ample data indicates quite the reverse. Patients, after all, are the ones who 
pay for expensive drugs when cheaper would do as well, and the ones who swallow 
dangerous drugs nudged to market by their manufacturers. 
 
 
Diversity of Care: A more diverse approach to disease management would involve collaboration 
amongst payers, providers and patients to endorse and educate on the use of a diversity of tools 
to support health, including holistic, natural, device-based treatments for disease and disease 
management.  
 
 
Figure 8 – 2x2 Matrix – Lindsay Roxon 
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Scenario Quadrant Characteristics 
1 - Individualism/Pharmacological 
•   Neoliberal values dominate 
•   Dominated by self-management of disease 
•   Pay for performance models push risk on physicians and patients, which decreases ease 
of access and equity, decreases physician profits 
•   Regulations around access (to limit cost & find efficiency) 
•   Precision medicine lives mostly as increasingly stratified medicine + cost of drugs 
becomes more expensive 
•   Winner takes all + monopolies of data & treatments 
•   Innovation is driven by the need to find efficiencies in the existing system. A focus on 
developing cheaper routes to commercialize pharmaceuticals.  
•   Clinical Trials are increasingly simulated as data available increases and capability of 
machine learning increases 
•   Reliance on tech to solve efficiency woes, but not necessarily to create solutions or 
improve the quality of treatment 
•   Pharma extends its value chain into hospitals to increase capacity for genetic testing to 
secure market for gene therapies and other, expensive niche products.  
•   Patient empowerment rhetoric (neo-liberalization of healthcare) is very strong.  
 
Richard spent the morning arranging his shoe collection. He had arranged them by colour and 
brand in his very large shoe closet. He has been living with cancer for 20 years, he thought often 
about how much different things would be if he had been diagnosed 10 years earlier. When he 
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was diagnosed he was immediately tested by physicians and prescribed a cocktail of medications 
that were customized for his genetic profile. It wasn’t perfect though and they said that it would 
extend his life by 5 – 15 years -- quite the range, but it seemed to be working. It was expensive, 
but thankfully he had premium insurance through his employer, AI Services Inc.. He barely saw 
a doctor now - his vitals were tracked in real time and analyzed by a lab remotely – where, he 
wasn’t sure – but he paid a lot for the service.  
 
Since the improvement of drug simulation process and a shortening of the patent protection to 10 
years from 20 years, there seemed to be new innovations all the time. There were products 
marketed to treat, prevent, augment, improve and generally optimize your biological condition. 
Frankly, no one knew if they even needed the drugs but they were hard to deny when they were 
marketed as completely customized to optimize with your own individual genome. He had heard 
that the science was still undecided about what the collective effect of this was, or how reliable 
biomarkers are as an indicator for certain diseases but, hey it seemed to be keeping him alive. He 
felt that if they were available it was his responsibility to take care of his health. He consulted a 
variety of services to verify, cross reference, assess his treatment options, his current health. 
Taking care of his health was paramount to everything else, it wasn’t just him, this seemed to be 
the case for all of his friends. Sipping his morning coffee, the cup started vibrating to remind him 
to eat and take his prescription medication before starting his day.   
 
Signals: 
 
1.   Human Organs on Chips 
2.   Genetic Testing at Hospitals 
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2 - Collectivism/ Pharmacological 
 
 
•   Pharma is incentivized by payers and regulation to focus R&D on preventative measures 
•   Over the counter, offloading of low complexity diseases to device and over the counter 
treatments.  
•   High policy regulation/databanks become ubiquitous and become combined funding 
initiatives between pharma and government to ensure that treatments are optimized.  
•   Many mergers between pharma & technology companies, a broader scope and role of 
Life Sciences companies.  
•   Value chain in hospitals is funded by pharma 
•   Mergers across industry -- retail and pharma etc.  
•   Quality of care improves overall but still missed opportunities for innovation 
•   International collaboration is incentivized to create more awareness of global health 
initiatives. 
•   Pharma continues to fund medical science in place of cash-strapped government.    
 
 
The new democratic government has spent years forging collaborative partnerships with 
pharmaceutical companies. Sharon, a government relations representative, absolutely loves her 
job. She collaborates with government to set targets for R&D for her company. Since the new 
regulations were put in place that measure real time impact to public health through widely worn 
wearable devices and mobile phones, it is critical that AbbVie work closely with government to 
make sure that R&D is targeted and endorsed by government. 
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Sometimes, she gets frustrated by the pressure to compete with international markets on 
innovation simply for political reasons, but innovation is innovation, and at least she knows she’s 
moving the needle somehow. China has been leading in preventative healthcare, so they’ve been 
getting a lot of pressure to develop products with the promise of preventing the development of 
disease – counteracting all the negative impact of lifestyle, low quality food and exposure to 
chemicals – the trouble is that China is staying ahead because they’re able to encourage lifestyle 
changes, not just market drugs but she knows that they’re doing more harm than good so day in 
and day out she pushes to create more collaboration, more innovation and work closer and closer 
with government. She’s excited to see what the future holds! 
 
Signals: 
1.   DePuy Synthes Acquires Tissue Regeneration System’s 3D Printing Technologies to 
Treat Bone Defects 
2.   Pioneering Data-Sharing Network Created to Accelerate Cancer Precision Medicine 
Development 
 
3 - Individualism/ Diversity 
 
 
•   Bedside pharmacy becomes popular and there is a reorganization of drug production 
value chain 
•   Reorganization and distribution of power of providers as more direct to consumer options 
become available.  
•   Non-traditional players play a disruptive role by driving efficiencies and innovation from 
outside the bounds of the conventional healthcare system.  
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•   Digital solutions that offer alternatives to pharmaceutical products are clinically approved 
and endorsed.  
•   Deregulation to allow for new entrants, new providers in hopes to lower cost of care. 
•   Patients work in a mix and match system, trying to have needs covered, need for much 
oversight and consulting by intermediaries which is not available to everyone.  
•   Possibility that unregulated emerging therapies cause harm as well as good 
 
 
Things have been challenging for Millie recently. She hadn’t worked in 15 years and since 
her husband lost his job they’ve had to be very conscious about the time and money that they 
spend on healthcare. He with diabetes and she with chronic pain, health is constantly top of 
mind. Looking back over the last decade, things have changed so much. The technology 
companies had doubled down on health innovations and had put pressure on insurance 
companies to begin to offer reimbursement for digital and holistic devices.  
 
Wearables and machine learning had made it possible, and affordable for these companies to 
collect clinical evidence to substantiate reimbursement and it changed everything. Except 
now the only problem was that no one knew what worked best – technology often operated 
outside of the physicians knowledge and every company claimed to have the best product. It 
was a fulltime job to weigh all the options and decide on the most affordable treatment plan – 
thankfully, she had the time. She was happy to have all the options, but still sometimes 
yearned for simpler days and less options when she could trust her doctor to make those 
decisions for her.  
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Signals: 
 
1.   Aetna & CVS Merger 
2.   Natural Cycles gains clinical approval in Europe 
 
 
4 - Collectivism/Diversity 
 
 
•   Connected care, social pressure, next generation “Big Health” approach 
•   Digital tools become ubiquitous and highly encouraged by public health officials and 
providers 
•   Collaboration between different stakeholders is incentivized and encouraged 
•   State plays a larger role in healthcare delivery 
•   The biohacking movement gains legitimacy as tools to track, measure and share results of 
self-experimentation grow.  
•   Diminished Pharma role has potential to reduce costs to system as a whole, but rising 
tech players may have a balancing effect 
 
Anna checked all of her monitoring devices to make sure they were all functioning and that her 
levels were sound, and then triple checked. She was going to be consulted by Amazon’s health 
representative tomorrow and she wanted to be ready. The more that she was able to prove that 
she had been following the regime that they had given her (customized for her genetic profile) 
the bigger the discount she and her family would receive on their purchases over the next six 
months. As an employee and manager she had exclusive access to anonymously trade her data 
for health discounts – provided that she was following the regime. Every month Amazon ran an 
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employee contest for extra discounts – usually as part of company research initiatives. She 
always participated. Beyond the incentives she loved being part of process of developing a new 
treatment that would change lives! Amazon had already developed a cancer drug recently moved 
to the open market. Very exciting! 
 
Growing up, she couldn’t have imagined being so diligent with her health, but now it was second 
nature. The kids participated too, although they were more motivated by the graphics and 
characters that their devices used to engage kids in staying healthy. She felt lucky – Amazon’s 
stats were out performing all other HMOs, mostly because everyone was always encouraging 
each other and checking out each other progress. It felt like being health responsible was helping 
everyone, not just her own family. 
 
Signals: 
1.   “Big Health” in China 
 
 
Summary of Findings: 
Stakeholder 
Group 
 
Incentive/Priorities Risk Opportunity 
Discovery –  
 
Pharma and 
risk-adapted 
corporate 
players 
 
 
 
As for-profit entities, 
pharma is incentivized to 
remain profitable and 
retain market control. In 
order to do this, they 
work to ensure 
exclusivity and access of 
their products, they 
attempt to secure and 
elongate profits from 
existing assets.  Pharma 
is faced with the tension 
of balancing the cost of 
Losing market share to 
digital therapeutics and 
other emerging players 
that have the ability to 
bypass the costly 
innovation barriers, 
iterate more quickly 
and capitalize on 
existing competencies 
in the digital space.  
De-risk R&D by finding 
efficiencies in the 
clinical trials through 
the use of digital tools 
and technologies. These 
include computer 
simulated trials, testing.  
 
Improve the efficacy of 
current pharmaceutical 
products through the use 
of digital sensors to 
ensure adherence.  
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innovation with potential 
for profitable outcomes, 
which acts as a barrier to 
innovation and reinforces 
the need to protect assets. 
 
Invest in and partner 
with digital natives to 
further the efficacy and 
reach of digital 
therapeutics.  
 
Access –  
 
Government 
and Insurance 
Companies 
 
 
Government is interested 
in decreasing public 
expenditure on 
healthcare via improved 
health outcomes and 
affordable therapeutics. 
Private payers are 
similarly incentivized to 
improve health outcomes 
and efficiencies to 
increase profitability and 
lower payout costs. 
However, they face less 
risk as they’re able to 
pass through costs to the 
broader system. 
Underregulating 
emerging players at the 
expense of public safety 
and decreasing 
healthcare efficiency.  
 
Overregulating 
emerging players at the 
expense of stifling 
innovation.  
 
Maintaining status quo, 
an overreliance on 
pharmaceutical 
innovation at the 
expense of realizing 
efficiencies and impact 
of alternatives like 
digital therapeutics.  
Working across 
industries to achieve 
optimal results.  
 
Funding innovators 
outside of the 
pharmaceutical space.  
 
Providing pathways for 
digital therapeutics and 
other alternatives.  
 
 
Data 
Ecosystem –  
 
Technology 
Companies 
 
Technology companies 
are interested in clearing 
regulatory hurdles for 
digital therapeutics and 
in the meantime 
demonstrating potential 
use-cases for digital 
therapeutics to gain 
credibility, iterate to 
improve product quality 
and begin to attract 
investors and generate 
profit. 
Failing to prove clinical 
use-cases, loss of 
investment and public 
trust in digital 
therapeutics.  
 
Failing to provide 
pathways to affordable, 
scalable means access.   
 
 
 
 
Alternatives to private 
health insurance, 
disruptive players in 
health insurance that 
endorse the use of 
digital therapeutics or 
other alternative 
therapies.  
Care –  
 
Patients and 
Physicians  
 
 
Patients and physicians 
are principally concerned 
with improving health 
outcomes and increasing 
the availability of 
affordable efficacious 
options. 
Limited access to 
pharmacological 
alternatives. Lack of 
access to truly 
individualized 
medicines that are more 
effective, less costly 
Provide patients with 
greater agency, 
education and access to 
digital therapeutics and 
alternatives that offer 
the opportunity to take a 
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and with fewer side-
effects.  
 
Physicians risk 
displacement by digital 
therapies that bypass 
the physician. Risk 
being replaced by 
professionals with 
alternative 
training/education 
capable of solving or 
addressing patient’s 
health challenges.  
more empowered role in 
individual care.  
 
Increase research and 
physician training on 
integrated, holistic, 
therapies that 
incorporate digital 
therapeutics as well as 
other alternatives. 
Decouple the notion of 
treatment with 
traditional 
pharmaceutical 
products.  
 
 
 
 
Table 1 – Summary of Findings – Lindsay Roxon 
 
 
Strategic Priorities 
 
Discovery - Pharmaceutical Companies and Risk-Adapted Corporate Players 
 
1.   Work to move beyond strictly the manufacturing and producing of pharmaceutical 
products to marketing, strategy and revenues models based on healthcare 
outcomes.  
2.   Work with government, providers and researchers to generate more cross-
functional problem solving and goal creation.  
3.   Continue to invest in new approaches to manufacturing and distribution of 
products to one that would support more personalized treatments – 3D printing, 
bedside pharmacy. 
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4.   Pharma to design business models for the future that poise them as a facilitator of 
science versus an innovator. 
 
Access- Government and Insurance Companies  
1.   Expedite approval pathways for non-pharmaceutical based products to gain 
appropriate data for reimbursement.   
2.   Develop a roadmap to supporting the digitization of hospitals, clinics and 
providers offices to create not only an integrated EMR, but also Learning Health 
Systems.  
3.   Establish collaborative relationships with providers, medical educators and health 
administrators to roadmap evolution of digital health and especially the changing 
nature of provider roles – assessing possibility, educational requirements, and 
system roadblocks. 
 
Data Ecosystem – Technology Companies and Emerging Players 
 
1.   Develop partnerships and means to collaborate with providers to ensure clinical 
relevancy.  
2.   Coordinate or create a governance body to create standardization across the 
industry to increase credibility and reliability of digital therapeutics.  
 
Care – Patients and Physicians  
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1.   Conceptualize and test models for care that support chronic disease patients and 
test the capability of digital therapeutics to assist this process.  
2.   Funding for medical practitioners to codify and educate other physicians.  
 
Conclusion 
 
There are innovations emerging from every direction that have a potential application to improve 
medical treatment and push Precision Medicine forward. This requires corporations entering the 
healthcare space to regard their role critically. In a capitalist society that has long prioritized 
economic growth over individual or ecological wellbeing, it will be important to look at 
healthcare businesses through a lens that is distinct from both the public and private sectors. 
Executives and policymakers may need to look at the successes and limitations of 
pharmaceutical companies. Is it time to ask the question, is wellbeing a right or a privilege? And 
what is an acceptable baseline? Going into the future, this may become an increasingly important 
question as new treatment possibilities emerge.  
 
Innovation beyond pharma is poised to massively disrupt healthcare in the coming decades. As 
consumers, care providers and technologists get smarter about creating effective approaches to 
treat health conditions that are customized to patients needs and the cost of clinically validating 
these approaches decreases, there is potential for physicians’ and patients’ tool box to broaden 
significantly. A resilient and socially conscious strategy for pharma may be to participate in the 
active disruption of their core product, leveraging existing resources to become a facilitator of 
science and innovation broadly. Perhaps, acting as manufacturers, facilitators and investors to 
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enable bottom up innovation (from citizen and HMO level) and act as stewards of collaboration 
in medical science.  
 
Policy makers, Health Administrators, payers should focus efforts and resources on clearing the 
pathways for innovation and adoption for players outside of pharma in order to allow physicians 
a broader toolkit to treat patients. This includes creating pathways for reimbursement for holistic 
care approaches, digital tools for health and natural remedies to incentivize innovation outside of 
pharma. By expanding the use of digital tools and greater collaboration between clinical 
validation organizations that create pathways for clinical approval for nonpharmacological 
treatments.  
 
In order to support this disruption it is critical that policy makers continue to build data 
infrastructure to support innovation at the clinic level. This means improving the EMR systems 
and equipping hospitals with Learning Health Systems that allow them to develop Real World 
Evidence to define and share best practises for individual disease states.  
 
True innovation may lie in the very complicated and complex terrain of creating open data 
networks, allowing open access and providing independent funding for scientists that work 
outside the realm of pharmacological research. Ultimately, creating a system where more bottom 
up innovation and collaboration is supported, with power distributed across major players in the 
healthcare. In addition, it is important that collaboration continue to be encouraged across 
geographies and between specialties for knowledge sharing and interdisciplinary problem 
solving.  
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Next Steps 
As a next step, it may be useful to more closely examine the use-cases for digital therapeutics 
including how they may work in a clinical setting. It would be worthwhile to more deeply 
understand the incentive structures around physicians and some of the risks and incentives 
involved in adopting a practise that is focus on a wider range of therapeutics. A potential 
outcome of this study might be understanding how the role of provider/physician should adapt 
for the next generation of medicine. As part of this study, it would be useful to understand which 
physician tasks are best and most likely to be displaced by technology in the coming years, and 
how physicians should be educated or upskilled to adapt and continue to push medicine forward 
rather than be incentivized to practise and promote the status quo.  
 
Limitations of this study 
This study was based exclusively on secondary research – it would have benefited from primary 
research and discussion with representatives of each stakeholder group to validate the ideas in 
the report. This study was intentionally broad, to provide an overview of some of the changes 
that may come to pass in the coming decades – this is also a limitation and there is a great 
amount of complexity within each of the major pillars that is discussed only at a high-level.  
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Appendix A 
 
Literature Review 
 
This review will present the academic literature that was referenced in the process of writing this 
paper. Each source will be reviewed and will include commentary on how the knowledge 
contributed to the overall development of the paper.  
 
This review is organized to represent the order in which I constructed my understanding of the 
topic through the existing literature. Each source will be covered in a summary that will address: 
what was learned, why the lessons are important, and how they apply to the project. 
  
Ultimately, this literature review was conducted to inform my analysis, using the Three Horizons 
tool to shed light on structural barriers and enablers to making precision medicine a reality. 
 
______________________________ 
 
Understanding the origins of the current system 
  
One of my first major questions in setting out on this journey was how our healthcare system had 
evolved to favour our current, interventional approach with medicine rather than a preventative 
or holistic approach to healing. My very broad and earnest questions were: how did our 
healthcare system evolve to become what it is? Why do we have the incentives in place that we 
do? How are these structural foundations still relevant today? Where are we seeing the 
100 
 
breakdown of this system? What might need to change to usher in the next generation of medical 
science?  
  
The idea of a healthcare system is a relatively new concept. In Brenda Helen Sheingold’s paper, 
“The History of Healthcare Quality,” she discusses the origin of the modern conception of 
healthcare as coming about as a result of a series of unrelated events, converging at different 
points in time to create the foundations of not only the American healthcare system, but systems 
around the world simultaneously. Through the discussion of “key tipping points” as a result of 
scientists, politicians and other changemakers, the modern healthcare system was conceived. A 
section of her paper focuses on the advent of pharmaceuticals in the late 1800s with the 
introduction of vaccines and penicillin — one of the first blockbuster drugs.  
 
Her paper, which focuses on the concept of quality of care and tracking measurable outcomes to 
improve care outcomes, mentions changes in industry and their impact on the conceptualization 
of quality in care. She cites Henry Ford’s Six Sigma approach and personal philosophy — “we 
are charged with discovering the best way of doing everything” — as a key influence on the 
approach and values that guided the early development of the healthcare system. Similarly today, 
we can track the zeitgeist on individualization and personalization across industries, including 
healthcare.  
  
Personalization as a movement is not solely restricted to healthcare. Perhaps as a backlash to 
mass production and globalization, where “same-same” had become the new normal, everything 
from technology to approaches to education and consumer brands have been exploring the value 
associated with personalization.   It seems that society at large is riding the wave of the 
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personalization trend that is focused on reorienting our definition of quality to one that focuses 
on value brought to the individual and realized outcomes rather than a product or service existing 
for its own sake.   
  
Conducting this research gave me insight into not only the origins of the system, but also some 
of the cultural beliefs that have led to some of the existing roles in the healthcare systems and 
some cultural beliefs that reinforce these roles. This was critical to providing the same structural 
framework for what might be important to include in the First Horizon’s “Evidence of the 
Future,” in that healthcare is as much a part of social and values trends as other consumer 
product industries.  
  
Basics in Health Economics 
 
In David Cohn’s book Sick: The Untold Story of America’s Health Care Crisis and the People 
that Pay the Price, he discusses the origins of the healthcare system in the United States. It was 
only in the 1920s that doctors and other caregivers learned enough about illness that they were 
able to make a significant difference in health outcomes for their patients. It was at this point that 
doctors began to charge more than patients could afford. It was this initial gap that created an 
opportunity for health insurers to develop, starting initially as nonprofit insurers based at a single 
hospital — Baylor Hospital in Dallas. Eventually this caught on, and nonprofit insurance became 
more widespread. Taking this as a signal for market opportunity, commercial insurance 
companies entered the arena. All the while, medical advancement was accelerating and with it, 
costs. Employers began to compete for talent by offering competitive health insurance packages, 
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and providers in turn were able to increase their rates. This trend continued to the point where 
health care costs are virtually unsustainable and even employers are beginning to cut 
reimbursements for care accessed. 
 
These learnings were important to understand as they create the cultural and economic 
foundations that underpin the healthcare system. In the United States, the healthcare industry was 
founded with a sound belief that each individual should receive equal access to care; however the 
involvement of commercial insurance has created tensions in the system that have led to grave 
inequities. It is critical to understand that the double-edged sword of this dynamic has also meant 
a healthcare industry that, despite its inefficiencies, is able to scale as a result of the profit it 
generates in order to continue to accelerate and create more specialized cures, which in turn 
creates more burdensome costs that are unsustainable. 
  
This is essential to understand as one of the key considerations in the implementation of any new 
treatment is its financial sustainability. We’ll look into the challenges of scalability from a health 
economics point of view when looking at rare diseases and the FDA approach to personalized 
medicine. While personalized medicine has the potential to create efficiencies, it is critical that 
there is a financial model in place that can facilitate discovery for individuals. As we’ve seen in 
the past, without consideration of the emerging changes, the potential of personalized medicines 
may only be realized by individuals who can afford them, further exacerbating the inequalities 
already driven by the healthcare system.  
  
Precision Medicine 
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In Richard Hodson’s paper “Precision Medicine” he explains that the “underlying concept of 
precision medicine, in which healthcare is individually tailored on the basis of a person’s genes, 
lifestyle and environment is not new: transfusion patients have been matched with donors 
according to blood type for more than a century. But advances in genetics, and the growing 
availability of health data, present an opportunity to make precise personalized patient care a 
clinical reality” (Hodson, 2017). 
 
This is important, as it explains why precision medicine has become so entangled with genetics-
based healthcare. The reason for this is not that precision medicine is only based on genetic 
profiling, but rather that it is one of the areas of personalized data for which there is significant 
research and an evidence-based approach to tailor care through biomarkers. 
  
The paper explains that the since the first “human genome was sequenced in 2001,” the cost for 
technology for genome sequencing is finally decreasing and availability of genome sequencing 
technology (particularly to diagnose rare disorders) is becoming more common. 
  
The paper clearly states that “Precision Medicine is powered by patient data. The health records 
and genetic codes of patients and healthy volunteers are vital, and help people influence their 
own health care and the direction of research. Securing participants’ trust is crucial to the success 
of large-scale programmes such as the US National Institutes of Health’s precision medicine 
Initiative.” 
  
In Francis Collins and Harold Varmus’ article “A New Initiative on Precision Medicine” the 
authors address former President Barack Obama’s decision to launch the precision medicine 
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Initiative. “Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to 
curing diseases like cancer and diabetes — and to give all of us access to the personalized 
information we need to keep ourselves and our families healthier”(President Obama, 2015). 
  
This paper clearly outlines some of the near- and long-term agendas for precision medicine. In 
the near-term it will be focused on cancers and then expanding to the broader range of health and 
disease. They identify that precision medicine has recently been made possible because new 
science is now within our reach, including “advances in basic research, including molecular 
biology, genomics, and bioinformatics. Furthermore, the initiative taps into converging trends of 
increased connectivity through social media and mobile devices, and Americans’ growing desire 
to be active partners in medical research.” 
  
Beyond the ways in which precision medicine may be applied to oncology, the paper discusses 
some of the changes that need to happen at the system level in order to facilitate precision 
medicine. “Achieving the goals of precision medicine will also require advancing the nation’s 
regulatory frameworks. To unleash the power of people to participate in research in innovative 
ways, the NIH is working with the Department of Health and Human Services to bring the 
Common Rule, a decades-old rule originally designed to protect research participants, more in 
line with the participants’ desire to be active partners in modern science.” 
  
The paper describes that in order to help speed discovery, the FDA is working with the scientific 
community to make sure its oversight of genomic technology supports innovation. It expresses 
its desire for this to eventually be collaborative with other health systems around the world. 
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The key finding here is that there is quite a bit of confusion around the term precision medicine, 
with many using the term to describe medicines that have been designed to target genetic 
profiles. In fact, precision medicine is much broader and includes (as stated by former President 
Barack Obama) the use of tools from fields such as bioinformatics and molecular biology.  This 
distinction is important to understand because the way that we think about and introduce 
precision medicine will differ depending on how those leading its charge understand the 
term.  That perspective will inform policy, clinical trial design, and ultimately other structural 
aspects of the healthcare system that have been designed around mass medicines.  
  
Inefficiencies of Care and the Clinical Trial 
  
“Millions of Americans get tests, drugs, and operations that won’t make them better, may cause 
harm, and cost billions.” — Atul Gawande (surgeon and public health researcher) 
 
After reading Nicholas Schork’s article “Imprecision Medicine.” which opens with a powerful 
comment, the importance and expansiveness of the emerging capabilities to collect, synthesize 
data as a result of monitoring devices, machine learning and Artificial Intelligence (A.I.) became 
apparent. “Every day, millions of people are taking medications that will not help them. The top 
ten highest-grossing drugs in the United States help between 1 in 25 and 1 in 4 of the people who 
take them. For some drugs, such as statins — routinely used to lower cholesterol — as few as 1 
in 50 may benefit. There are even drugs that are harmful to certain ethnic groups because of the 
bias towards white Western participants in classical clinical trials.” (Schork, 2015) He argues 
that there is a need to rethink the way pharmaceutical products are developed and prescribed in 
order to address the inefficiencies that are created when prescribing the wrong drug.  She 
believes that in order to push forward the precision medicine movement, the healthcare system 
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needs to facilitate a means for N-of-1, or trials that a trial where a single patient constitutes the 
entire trial, or individual trials) approach to testing, validating and commercializing medicines.  
  
She states that while physicians have always done this in an ad hoc way, few clinicians or 
researchers have formalized the approach into well-designed trials, “usually a handful of 
measurements are taken, and only during treatment.” 
  
She states simply that “if enough data are collected over a sufficiently long time, and appropriate 
control interventions are used, the trial participant can be confidently identified as a responder or 
non responder to a treatment.  Aggregated results of many N-of-1 trials (all carried out in the 
same way) will offer information about how to better treat subsets of the population or even the 
population at large” (Schork, 2015). 
  
She goes on to identify a few possibilities to see this process come to life. This includes:   
1) Exploiting the diversity of health-monitoring devices  
2) Identifying new ones and identifying appropriate disease biomarkers, such as tumour 
DNA circulating in the bloodstream.  
3) A cultural shift in regulatory agencies, pharmaceutical companies, and at the clinic 
level. 
  
She goes on to discuss how researchers will often run post-trial analyses to try to identify why 
certain patients don’t perform well in clinical trials. In these post-trial analyses, researchers will 
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try to match results with chromosomal or genetic profiles to try to determine a correlation 
between performance and the individual profiles of a certain patient. 
  
Conventional phase III trials involve thousands of people. The intervention being tested 
is often given at random to one group while another group receives a sham treatment, 
such as a sugar pill or the standard treatment that physicians would give such patients. 
Because scant data are collected on factors such as genetics, lifestyles and diets, the 
results of these trials often indicate the need for yet another study to validate the 
effectiveness of the intervention among the apparent responders and to establish the 
underlying mechanisms. (Schork, 2015) 
 
Schork’s article made it clear that, according to her, the key to integrating more holistic measures 
to determine the effectiveness of a drug lay in the ability to track and integrate data in a more 
thoughtful way — essentially a technology and design challenge.  
  
He points out that there are challenges in N-of-1 trials beyond logistics. For example, in creating 
studies to measure a population-based response to something, it may be difficult to control 
variables, since an effective N-of-1 trial would require repeated and efficiently measured results. 
The added complication is that it is not always clear what to measure, in certain conditions where 
a biomarker hasn’t been identified or a condition presents in an idiosyncratic way in different 
patients. 
 
He cites rare diseases as a proxy for observing the effectiveness of N-of-1 trials. He also 
indicates that although N-of-1 trials are more costly in certain cases, they tend to actually reduce 
cost over time because treatments are more effective. 
  
He also cites the need to create an understanding of individual or personal thresholds for 
uncovering diseases. “For instance, US physicians generally view levels of a blood protein called 
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CA125 greater than 30 or 35 as an indication of ovarian cancer. However, a level of 20 or 25 
may be a cause for concern if the person's average CA125 levels hovered around 10 or 15 over 
the previous year.” (Schork, 2015)  
 
He discusses some of the barriers to making clinical trials a reality, including cultural changes  at 
regulatory agencies, with physicians and researchers moving away from classical clinical trials. 
She suggests new profit models for pharmaceutical companies that let them move away from 
drugs that can be used by thousand or millions of people. He proposes reducing the cost of 
genetic sequencing and funding more research on effective biomarkers, monitoring devices, 
study designs, and analysis methods. Her report seems to indicate that while N-of-1 trials are not 
likely to solve all the challenges in the healthcare system, they are “a key component will be 
transforming everyday clinical care into solid N-of-1 trials.” 
  
His paper was important in that it outlines one of the key challenges and opportunities in 
precision medicine with respect to the way drugs are trialled and approved. He references rare 
diseases, the need for data tools and infrastructure, while also stating that N-of-1 trials could and 
should be made a part of regular clinical practice. 
  
A follow up paper co-authored by Schork, Lillie, Patay, Diamant, Issell and Topol, “The n-of-1 
clinical trial: the ultimate strategy for individualizing medicine?” reinforces this perspective. 
This paper reviews the “history, motivation and design of n-of-1 trials and emphasizes the great 
utility of modern wireless medical monitoring devices in their execution.” It ultimately argues 
that n-of-1 trials “demand serious attention among the health research and clinical care 
communities given the contemporary focus on individualized medicine.” 
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He mentions that, at the moment only 10% of labels for FDA-approved drugs contain 
pharmacogenomic information and that the “FDA is actively involved in creating a streamlined 
review approach to diagnostic companion tests with therapeutics where n-of-1 trials could play a 
role in facilitating the approval process.” However, she notes that these approaches, while a step 
forward, are not truly individualized but rather simply a stratification of patients into subgroups. 
She goes on to discuss different approaches to trial design and data analysis for trials. 
  
The ability to leverage wireless medical devices make n-of-1 trials a practical possibility in a 
way that was not feasible in the past. They argue that in order to enable successful trials, the 
patient experience must be completely seamless to allow for the accurate measurement of 
relevant clinical end points. “Remote clinical phenotyping and wireless devices have enormous 
potential in this light.” As discussed in Smriti Sakher’s project The Walled Gardens of Care, 
many health monitoring devices have not yet proven to be reliable in clinical settings, and until 
they are, they cannot facilitate n-of-1 trials. 
  
The authors cite the following barriers to be overcome in order to facilitate n-of-1 trials: a 
nationwide agenda in individualized medicine; appropriate training for physicians; early phase 
trials; leveraging medical records; treatment repositioning; and clinical equipoise. 
 
Patient Empowerment: Rallying Cry or Passing the Buck?  
  
Another perspective on personalized medicine is offered in the paper “Personalized Genomic 
Medicine and the Rhetoric of Empowerment,”(Juengst, Flatt and Settersten, 2012).  The authors 
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argue that personalized medicine may offer an opportunity for medical breakthrough, but warn 
that the patient empowerment rhetoric may be overstating the benefits to patients. It goes on to 
insist that the benefits and challenges to patients in a system that is highly individualistic need to 
be carefully weighed. The paper cites three groups of stakeholders that are “heavily invested in 
empowerment rhetoric”:  
1) direct-to-consumer genomic scanning companies and the “early adopters of their 
services  
2) the leaders of genomic medicine programs at premier biomedical research and health 
care institutions  
3) genomic medicine’s government sponsors and advocacy groups 
  
The authors warn that while there are many positives that can come of this movement, “the shift 
should prompt concern within the personalized genomic medicine movement because it may 
increase pressure on patients to comply with physicians’ recommendations.” They go on to say 
that what is “even more worrisome is that individuals who are unable to become a “health-
creating person” or who do not make the “right” health choices are easily “marked out as 
irresponsible and hence unfit to be self-governing citizens.” 
  
This paper offered a perspective into some of the challenges of personalized medicine. While 
this project won’t be focusing on the patient point of view, it is still critical to represent some of 
the challenges that physicians may face in the near- and long-term future as the benefits of 
precision medicine come to bear. Similarly, it becomes an issue for which we need to design 
when retooling the healthcare system to make personalized medicine possible.  
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In the paper "Patent Cliff And Strategic Switch: Exploring Strategic Design Possibilities In The 
Pharmaceutical Industry" (Song and Han, 2016), the authors detail some of the major challenges 
that pharmaceutical companies currently face as it becomes more and more difficult to create 
blockbuster drugs. Other authors state that the “low hanging fruits” in drug development have 
been picked to a large extent (Williams, 2011) and it is necessary to protect the pharmaceutical 
company’s revenue stream by measures other than unjustifiably abusing the intellectual property 
right at the expense of competition and public welfare (Glasgow, 2001). Therefore, 
pharmaceutical companies are encouraged to focus on specialty drugs with low substitution 
potential by creating “niche busters”or drugs that target rare and low incidences diseases. 
(Dolgin 2010; Kakkar and Dahiya, 2014).  This is important as it may provide some indication 
on the willingness of pharmaceutical companies to begin to innovate in more niche markets that 
could eventually lead to more personalized drugs, if the environmental conditions (regulatory 
and reimbursement) are favourable. 
  
In the paper “Design and Implementation of N-of-1 Trials: A User’s Guide” (Kravitz et al., 2014), 
the authors provided a detailed guide to understand the history of n-of-1 trials, their utility, and 
the possibilities that they present to the healthcare system. According to the paper, “N-of-1 trials 
are a specific form of randomized or balanced designs characterized by periodic switching from 
active treatment to placebo or between active treatments (“withdrawal-reversal” designs). N-of-1 
trials were introduced to clinicians by Hogben and Sim as early as 1953, but it took 30 years for 
the movement to find an effective evangelist in the person of Gordon Guyatt at McMaster 
University.” 
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The paper goes on to say that the success of an n-of-1 trial is highly dependent on the 
commitment and collaboration of both the clinician and the patient. The authors point out that n-
of-1 trials are “particularly suited to chronic conditions,” meaning that in our current 
environment of rising healthcare costs and increased chronic disease, the savings to the 
healthcare system could be substantial. The paper goes on to detail how clinicians can run these 
trials. This was interesting as it is indicative of the high reliance on primary caregivers and other 
clinicians in running trials, which is a significant change from the current model that relies on a 
highly hierarchical approach to recruit and compensate study leads. 
  
The paper outlines a number of opportunities and challenges. The authors indicate that n-of-1 
trials are helpful in identifying “ineffective therapies, thus reducing polypharmacy, minimizing 
adverse effects, and conserving health care resources.” The paper underscores that there is a 
possibility that patients may become more engaged in their own care, which is associated with 
better outcomes. The third opportunity presented by the paper is that n-of-1 trials can blur the 
boundaries between clinical practice and clinical research, making research more like practice 
and practise more like research, which would increase relevance and generalizability of results, 
and increase opportunities for creating clinical evidence. 
  
The barriers identified by the paper include the need for Learning Healthcare Systems (LHS) or 
intelligent data infrastructure to collect and store data, the need for research ethics boards to 
approve the validity of an n-of-1 approach, and the need for some automation of clinical data to 
make analysis more accessible for patients and physicians. 
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In Chapter 3 of the paper, The Design and Implementation of n-of-1 trials, “The Financing of an 
n-of-1 Approach” (Kravitz et al., 2014), the authors discuss some of the challenges that may be 
faced when they are put into practise.  
 
Despite their many potential benefits, n-of-1 trials have not become part of mainstream 
clinical medicine, and to our knowledge have never been a covered benefit in any 
insurance plan (private or government run) in the United States or Canada. A 2010 
systematic review found 108 unique trial protocols from the years 1986 to 2010; the vast 
majority had authors from Canada (35%), Europe (26%), or the United States (22%). N-
of-1 trial services have been run almost exclusively by academic centers with little reach 
into community practice in the United States; somewhat broader reach has been achieved 
in Australia. (Kravitz et al., 2014) 
  
The article concludes by indicating that the reimbursement or financing for n-of-1 trials will be 
largely dependent on the ability of technology companies to facilitate an accurate and reliable 
way to collect, store, and analyze data. Once these systems are in place it will be more cost-
effective to run and easier to scale. 
  
Beyond recognizing some of the technical barriers, the paper recommends more engagement 
with physicians to run n-of-1 trials in identifying patients and analyzing results. 
  
Understanding the Data Environment 
  
From readings in understanding how we might make trialing of drugs possible at the clinician 
level, it became obvious that a lack of digital infrastructure and reliable monitoring devices 
makes such trialing difficult.. In order to further understand the gaps and the possibilities, 
research was conducted to get a sense of the optimal data infrastructure ecosystem. 
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In "Toward A Science Of Learning Systems: A Research Agenda For The High-Functioning 
Learning Health System" (Friedman et al., 2014) the authors detail the anatomy of a Learning 
Health System, which would provide the “capability to share data, and harness its potential to 
generate knowledge rapidly and inform decisions, can have transformative effects that improve 
health. The infrastructure to achieve this goal at scale — marrying technology, process and 
policy — is commonly referred to as the Learning Health System.” (Friedman et al., 2014) 
  
The paper goes on to mention that LHS would provide health care workers — from 
administrators to physicians — an opportunity to study the system itself and improve. “There is a 
growing recognition of the US healthcare system's inability to routinely study its own behaviour; 
an LHS would provide such capability, and would significantly address many of the current 
challenges faced by the system.” The paper goes on to explain that developing effective LHS 
will require complex processes of stakeholder engagement. “From these developments, it is 
evident that achievement of a national-scale LHS will not be the work of a single organization, 
stakeholder group, or governmental entity. Rather, it is anticipated that the LHS will require 
active participation of and cooperation among multiple and diverse stakeholders, nationwide and 
ultimately globally.” 
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Regulation of Personalized Approaches to Medicine 
  
In a paper written by the U.S. Food and Drug Administration, the authors outline the ways in 
which the FDA will facilitate personalized medicine. 
  
“For well over a decade, personalized medicine has changed the FDA while the FDA, in turn, 
has changed personalized medicine”(citation, date) 
 
The FDA has a long history with personalized medicine beginning in the 1980s with the 
characterization of molecular characteristics of disease that led to personalized therapeutics. 
 
Shortly following the announcement of the completion of the human genome project, 
each of the FDA’s medical product centers — the Center for Drug Evaluation and 
Research (CDER), the Center for Biologics Evaluation And Research, the Center for 
Devices and Radiological Health - as well as the national Center for Toxicological 
Research, took steps to begin to put into place regulatory process policies and 
infrastructure to meet challenges. (Food and Drug Administration, 2013) 
 
 
 The FDA’s approach is mostly comprised of developing committees and expertise around 
Personalized Medicine within the organization.  The FDA has been actively working on 
streamlining processes for devices to be approved since the practise of precision medicine will 
often require devices working together. 
  
They are also working to speed the development of new therapeutics by “developing regulatory 
science standards, reference libraries, research methods and tools that are needed for integrating 
genetic and other biomarker information into drug and device development and clinical decision 
making. These include: Biomarker Qualification Program, MicroArray and Sequencing Quality 
116 
 
Control Project, Genomic Reference Library for Evaluating Whole Genome Sequencing 
Platforms (to streamline approach and determine value on an individual level), Virtual 
Physiological Patient (incorporating computational model into clinical practise), High-
Performance Integrated Virtual Environment for Next-Generation Sequencing Analysis 
Infrastructure (cloud for storage of extra-large data), Development of High Resolution Human 
Leukocyte Antigen Typing (Database), Development of Molecular Tools to Facilitate Blood 
Group Typing (Database), Clinical Trial Designs and Methodologies. 
  
The paper outlines the following challenges: Limited understanding of the intrinsic 
biology of disease, Common conditions involving multiple genes/biomarkers, an outdated 
disease classification system, lack of infrastructure, clinical implementation of new diagnostics, 
investment uncertainties, and access to personalized therapeutics. 
  
The Role of Pharmacy 
  
In the paper “Making Individualized Drugs a Reality” (Schellekens et al., 2017), the authors 
argue that while precision medicine is the aspiration, it may be a challenge to bring the 
aspirational visual into reality as a result of regulatory hurdles. The authors argue that the 
challenges are not so much in the regulatory environment but rather in how medication is 
manufactured. 
  
The starting point of personalized medicine can be traced to the completion of the Human 
Genome Project, which sequenced almost the entire human genome, in 2001. Since then 
however, only a limited number of personalized pharmaceutical treatments have reached 
patients. Technical issues like the lack of validated genetic tests and biomarkers to predict 
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patient responses are often cited as reason for the disappointingly slow rollout of 
precision medicines.(Schellekens et al., 2017) 
  
The author, however, argues that the current pharmaceutical model is unsuitable for creating 
precision medicines, since it takes about three years “from the time a company submits a new 
drug application to the FDA or EMA before it reaches patients.” This is inherently unsuitable for 
an individualized product that is in demand at the moment. 
  
As the approval process is currently structured, precisely the same product must be used during 
preclinical and clinical development (although experimentation with dosage is encouraged), and 
the marketed product must also be the same formulation. Any change in the product or in the 
way it is used requires all the testing to be repeated, adding years to the process. 
  
The paper introduces the concept of “bedside pharmaceuticals” as a way to solve these 
challenges. “When production and treatment are under the responsibility of the same institute, no 
marketing authorization is needed. This approach bypasses the pharmaceutical industry.” 
  
Drug production at that small level is common practice in the pharmaceutical industry during the 
discovery and early development phase of biopharmaceuticals — meaning the technology is 
available for production in hospital pharmacies. 
  
In terms of healthcare economics as a whole, the main contributor to soaring costs is 
innovation in a market that is driven by what is offered, rather than by medical need. 
There is no reason to expect this dynamic to change, despite the advent of precision 
medicine. If economics are driven by fee-for-service rather than by medical need, there is 
no reason why existing models of precision medicine would alter cost-effectiveness. 
(Schellekens et al., 2017) 
 
